CN110478085A - Heart valve prosthesis and its fillable structure - Google Patents
Heart valve prosthesis and its fillable structure Download PDFInfo
- Publication number
- CN110478085A CN110478085A CN201910864378.9A CN201910864378A CN110478085A CN 110478085 A CN110478085 A CN 110478085A CN 201910864378 A CN201910864378 A CN 201910864378A CN 110478085 A CN110478085 A CN 110478085A
- Authority
- CN
- China
- Prior art keywords
- ring cavity
- end ring
- proximal end
- valve prosthesis
- heart valve
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000003709 heart valve Anatomy 0.000 title claims abstract description 278
- 230000017531 blood circulation Effects 0.000 claims abstract description 18
- 230000000670 limiting effect Effects 0.000 claims abstract description 3
- 239000000463 material Substances 0.000 claims description 73
- 210000000709 aorta Anatomy 0.000 claims description 27
- 239000013013 elastic material Substances 0.000 claims description 9
- 229920002725 thermoplastic elastomer Polymers 0.000 claims description 6
- 229920002614 Polyether block amide Polymers 0.000 claims description 5
- 229920000126 latex Polymers 0.000 claims description 3
- 239000004816 latex Substances 0.000 claims description 3
- 239000000178 monomer Substances 0.000 claims description 3
- 229920002379 silicone rubber Polymers 0.000 claims description 2
- 239000011797 cavity material Substances 0.000 description 191
- 238000011049 filling Methods 0.000 description 86
- 210000001765 aortic valve Anatomy 0.000 description 35
- 210000002216 heart Anatomy 0.000 description 35
- 210000001519 tissue Anatomy 0.000 description 31
- 239000004744 fabric Substances 0.000 description 29
- 239000012530 fluid Substances 0.000 description 26
- -1 polytetrafluoroethylene Polymers 0.000 description 25
- 210000005240 left ventricle Anatomy 0.000 description 22
- 150000001875 compounds Chemical class 0.000 description 18
- 210000004204 blood vessel Anatomy 0.000 description 16
- 239000004593 Epoxy Substances 0.000 description 14
- 238000002513 implantation Methods 0.000 description 14
- 238000000034 method Methods 0.000 description 14
- 239000007789 gas Substances 0.000 description 13
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
- 239000003822 epoxy resin Substances 0.000 description 12
- 239000007788 liquid Substances 0.000 description 12
- 229920000647 polyepoxide Polymers 0.000 description 12
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 12
- 239000004810 polytetrafluoroethylene Substances 0.000 description 12
- 238000010586 diagram Methods 0.000 description 11
- 238000001727 in vivo Methods 0.000 description 11
- 239000008280 blood Substances 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- 210000003484 anatomy Anatomy 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 210000004351 coronary vessel Anatomy 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 239000004677 Nylon Substances 0.000 description 7
- 208000006011 Stroke Diseases 0.000 description 7
- 230000006835 compression Effects 0.000 description 7
- 238000007906 compression Methods 0.000 description 7
- 239000002872 contrast media Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000007943 implant Substances 0.000 description 7
- 229920001778 nylon Polymers 0.000 description 7
- 238000007789 sealing Methods 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 239000003356 suture material Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 239000004642 Polyimide Substances 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- 125000001931 aliphatic group Chemical group 0.000 description 6
- 125000000217 alkyl group Chemical group 0.000 description 6
- 238000013459 approach Methods 0.000 description 6
- 210000001367 artery Anatomy 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 239000000835 fiber Substances 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 210000004115 mitral valve Anatomy 0.000 description 6
- 229910001000 nickel titanium Inorganic materials 0.000 description 6
- HLXZNVUGXRDIFK-UHFFFAOYSA-N nickel titanium Chemical compound [Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni] HLXZNVUGXRDIFK-UHFFFAOYSA-N 0.000 description 6
- 229920001721 polyimide Polymers 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 229910001220 stainless steel Inorganic materials 0.000 description 6
- 239000010935 stainless steel Substances 0.000 description 6
- 230000003068 static effect Effects 0.000 description 6
- CTKINSOISVBQLD-UHFFFAOYSA-N Glycidol Chemical compound OCC1CO1 CTKINSOISVBQLD-UHFFFAOYSA-N 0.000 description 5
- 239000004698 Polyethylene Substances 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 230000008602 contraction Effects 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 229910052751 metal Inorganic materials 0.000 description 5
- 239000002184 metal Substances 0.000 description 5
- 229920000573 polyethylene Polymers 0.000 description 5
- 239000005020 polyethylene terephthalate Substances 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- RNLHGQLZWXBQNY-UHFFFAOYSA-N 3-(aminomethyl)-3,5,5-trimethylcyclohexan-1-amine Chemical compound CC1(C)CC(N)CC(C)(CN)C1 RNLHGQLZWXBQNY-UHFFFAOYSA-N 0.000 description 4
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 229910045601 alloy Inorganic materials 0.000 description 4
- 239000000956 alloy Substances 0.000 description 4
- 238000005452 bending Methods 0.000 description 4
- 238000009954 braiding Methods 0.000 description 4
- 230000002308 calcification Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 238000004891 communication Methods 0.000 description 4
- 238000002716 delivery method Methods 0.000 description 4
- 238000009940 knitting Methods 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 210000003102 pulmonary valve Anatomy 0.000 description 4
- 238000005086 pumping Methods 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000009958 sewing Methods 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 229960001866 silicon dioxide Drugs 0.000 description 4
- 238000007711 solidification Methods 0.000 description 4
- 230000008023 solidification Effects 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- RPNUMPOLZDHAAY-UHFFFAOYSA-N Diethylenetriamine Chemical compound NCCNCCN RPNUMPOLZDHAAY-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 239000004952 Polyamide Substances 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 125000002252 acyl group Chemical group 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000005520 cutting process Methods 0.000 description 3
- YMHQVDAATAEZLO-UHFFFAOYSA-N cyclohexane-1,1-diamine Chemical class NC1(N)CCCCC1 YMHQVDAATAEZLO-UHFFFAOYSA-N 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 229920001971 elastomer Polymers 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 150000002118 epoxides Chemical class 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 230000005012 migration Effects 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- JAYXSROKFZAHRQ-UHFFFAOYSA-N n,n-bis(oxiran-2-ylmethyl)aniline Chemical compound C1OC1CN(C=1C=CC=CC=1)CC1CO1 JAYXSROKFZAHRQ-UHFFFAOYSA-N 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 229920002647 polyamide Polymers 0.000 description 3
- 229920000570 polyether Polymers 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- KAKZBPTYRLMSJV-UHFFFAOYSA-N vinyl-ethylene Natural products C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 description 3
- 238000009941 weaving Methods 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- LCFVJGUPQDGYKZ-UHFFFAOYSA-N Bisphenol A diglycidyl ether Chemical compound C=1C=C(OCC2OC2)C=CC=1C(C)(C)C(C=C1)=CC=C1OCC1CO1 LCFVJGUPQDGYKZ-UHFFFAOYSA-N 0.000 description 2
- 206010008190 Cerebrovascular accident Diseases 0.000 description 2
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 2
- 102000016942 Elastin Human genes 0.000 description 2
- 108010014258 Elastin Proteins 0.000 description 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N N-phenyl amine Natural products NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 229920004933 Terylene® Polymers 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000004844 aliphatic epoxy resin Substances 0.000 description 2
- IMUDHTPIFIBORV-UHFFFAOYSA-N aminoethylpiperazine Chemical compound NCCN1CCNCC1 IMUDHTPIFIBORV-UHFFFAOYSA-N 0.000 description 2
- 238000002583 angiography Methods 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 206010002906 aortic stenosis Diseases 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- XUCHXOAWJMEFLF-UHFFFAOYSA-N bisphenol F diglycidyl ether Chemical compound C1OC1COC(C=C1)=CC=C1CC(C=C1)=CC=C1OCC1CO1 XUCHXOAWJMEFLF-UHFFFAOYSA-N 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 229910052804 chromium Inorganic materials 0.000 description 2
- 239000011651 chromium Substances 0.000 description 2
- 229910017052 cobalt Inorganic materials 0.000 description 2
- 239000010941 cobalt Substances 0.000 description 2
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 229920002549 elastin Polymers 0.000 description 2
- 239000000806 elastomer Substances 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 210000003238 esophagus Anatomy 0.000 description 2
- 229920000295 expanded polytetrafluoroethylene Polymers 0.000 description 2
- 210000001105 femoral artery Anatomy 0.000 description 2
- 229920002313 fluoropolymer Polymers 0.000 description 2
- 239000004811 fluoropolymer Substances 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 210000002837 heart atrium Anatomy 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 229910052750 molybdenum Inorganic materials 0.000 description 2
- 239000011733 molybdenum Substances 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 229910052759 nickel Inorganic materials 0.000 description 2
- 210000003516 pericardium Anatomy 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 229920000139 polyethylene terephthalate Polymers 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229930195734 saturated hydrocarbon Natural products 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 229920002545 silicone oil Polymers 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- BQCIDUSAKPWEOX-UHFFFAOYSA-N 1,1-Difluoroethene Chemical compound FC(F)=C BQCIDUSAKPWEOX-UHFFFAOYSA-N 0.000 description 1
- VILCJCGEZXAXTO-UHFFFAOYSA-N 2,2,2-tetramine Chemical compound NCCNCCNCCN VILCJCGEZXAXTO-UHFFFAOYSA-N 0.000 description 1
- DGXAGETVRDOQFP-UHFFFAOYSA-N 2,6-dihydroxybenzaldehyde Chemical compound OC1=CC=CC(O)=C1C=O DGXAGETVRDOQFP-UHFFFAOYSA-N 0.000 description 1
- WVXLLHWEQSZBLW-UHFFFAOYSA-N 2-(4-acetyl-2-methoxyphenoxy)acetic acid Chemical compound COC1=CC(C(C)=O)=CC=C1OCC(O)=O WVXLLHWEQSZBLW-UHFFFAOYSA-N 0.000 description 1
- HPILSDOMLLYBQF-UHFFFAOYSA-N 2-[1-(oxiran-2-ylmethoxy)butoxymethyl]oxirane Chemical compound C1OC1COC(CCC)OCC1CO1 HPILSDOMLLYBQF-UHFFFAOYSA-N 0.000 description 1
- AOBIOSPNXBMOAT-UHFFFAOYSA-N 2-[2-(oxiran-2-ylmethoxy)ethoxymethyl]oxirane Chemical compound C1OC1COCCOCC1CO1 AOBIOSPNXBMOAT-UHFFFAOYSA-N 0.000 description 1
- CJNZAXGUTKBIHP-UHFFFAOYSA-N 2-iodobenzoic acid Chemical compound OC(=O)C1=CC=CC=C1I CJNZAXGUTKBIHP-UHFFFAOYSA-N 0.000 description 1
- WFCQTAXSWSWIHS-UHFFFAOYSA-N 4-[bis(4-hydroxyphenyl)methyl]phenol Chemical compound C1=CC(O)=CC=C1C(C=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 WFCQTAXSWSWIHS-UHFFFAOYSA-N 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 206010002915 Aortic valve incompetence Diseases 0.000 description 1
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- 206010003671 Atrioventricular Block Diseases 0.000 description 1
- 241000282817 Bovidae Species 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 229920004934 Dacron® Polymers 0.000 description 1
- WPYCRFCQABTEKC-UHFFFAOYSA-N Diglycidyl resorcinol ether Chemical compound C1OC1COC(C=1)=CC=CC=1OCC1CO1 WPYCRFCQABTEKC-UHFFFAOYSA-N 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- IBFYXTRXDNAPMM-BVTMAQQCSA-N Geniposide Chemical compound O([C@@H]1OC=C([C@@H]2[C@H]1C(=CC2)CO)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O IBFYXTRXDNAPMM-BVTMAQQCSA-N 0.000 description 1
- IBFYXTRXDNAPMM-FZEIBHLUSA-N Geniposide Natural products COC(=O)C1=CO[C@@H](O[C@H]2O[C@@H](CO)[C@H](O)[C@@H](O)[C@@H]2O)[C@H]2[C@@H]1CC=C2CO IBFYXTRXDNAPMM-FZEIBHLUSA-N 0.000 description 1
- HSRJKNPTNIJEKV-UHFFFAOYSA-N Guaifenesin Chemical compound COC1=CC=CC=C1OCC(O)CO HSRJKNPTNIJEKV-UHFFFAOYSA-N 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 229920000271 Kevlar® Polymers 0.000 description 1
- 229920006370 Kynar Polymers 0.000 description 1
- JHWNWJKBPDFINM-UHFFFAOYSA-N Laurolactam Chemical compound O=C1CCCCCCCCCCCN1 JHWNWJKBPDFINM-UHFFFAOYSA-N 0.000 description 1
- 241000289581 Macropus sp. Species 0.000 description 1
- ZNYLTRCVMZZXGQ-UHFFFAOYSA-N N,N-bis(oxiran-2-ylmethyl)aniline Chemical compound C(C1CO1)N(C1=CC=CC=C1)CC1CO1.C(C1CO1)N(C1=CC=CC=C1)CC1CO1 ZNYLTRCVMZZXGQ-UHFFFAOYSA-N 0.000 description 1
- 229920000299 Nylon 12 Polymers 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 206010061481 Renal injury Diseases 0.000 description 1
- 239000004959 Rilsan Substances 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 229910001069 Ti alloy Inorganic materials 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- QYKIQEUNHZKYBP-UHFFFAOYSA-N Vinyl ether Chemical compound C=COC=C QYKIQEUNHZKYBP-UHFFFAOYSA-N 0.000 description 1
- QLBRROYTTDFLDX-UHFFFAOYSA-N [3-(aminomethyl)cyclohexyl]methanamine Chemical compound NCC1CCCC(CN)C1 QLBRROYTTDFLDX-UHFFFAOYSA-N 0.000 description 1
- YIMQCDZDWXUDCA-UHFFFAOYSA-N [4-(hydroxymethyl)cyclohexyl]methanol Chemical compound OCC1CCC(CO)CC1 YIMQCDZDWXUDCA-UHFFFAOYSA-N 0.000 description 1
- 230000009692 acute damage Effects 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 230000001194 anti-hemostatic effect Effects 0.000 description 1
- 230000002965 anti-thrombogenic effect Effects 0.000 description 1
- 206010002895 aortic dissection Diseases 0.000 description 1
- 201000002064 aortic valve insufficiency Diseases 0.000 description 1
- VGLLGNISLBPZNL-RBUKDIBWSA-N arborescoside Natural products O=C(OC)C=1[C@@H]2C([C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=1)=C(CO)CC2 VGLLGNISLBPZNL-RBUKDIBWSA-N 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 239000010426 asphalt Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000000560 biocompatible material Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 239000004568 cement Substances 0.000 description 1
- 230000007213 cerebrovascular event Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000001595 contractor effect Effects 0.000 description 1
- 239000011353 cycloaliphatic epoxy resin Substances 0.000 description 1
- ZWAJLVLEBYIOTI-UHFFFAOYSA-N cyclohexene oxide Chemical compound C1CCCC2OC21 ZWAJLVLEBYIOTI-UHFFFAOYSA-N 0.000 description 1
- FWFSEYBSWVRWGL-UHFFFAOYSA-N cyclohexene oxide Natural products O=C1CCCC=C1 FWFSEYBSWVRWGL-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000003073 embolic effect Effects 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- 229940052303 ethers for general anesthesia Drugs 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000005429 filling process Methods 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 238000002594 fluoroscopy Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000009963 fulling Methods 0.000 description 1
- 238000011990 functional testing Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 230000001435 haemodynamic effect Effects 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 206010020871 hypertrophic cardiomyopathy Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 239000004761 kevlar Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000037806 kidney injury Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000012866 low blood pressure Diseases 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000002715 modification method Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 239000004848 polyfunctional curative Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 210000001147 pulmonary artery Anatomy 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 239000012858 resilient material Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 210000005241 right ventricle Anatomy 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 239000005060 rubber Substances 0.000 description 1
- 239000003566 sealing material Substances 0.000 description 1
- 229920000260 silastic Polymers 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 238000005245 sintering Methods 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000003351 stiffener Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229910052715 tantalum Inorganic materials 0.000 description 1
- GUVRBAGPIYLISA-UHFFFAOYSA-N tantalum atom Chemical compound [Ta] GUVRBAGPIYLISA-UHFFFAOYSA-N 0.000 description 1
- 239000004753 textile Substances 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 229960001124 trientine Drugs 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 231100000216 vascular lesion Toxicity 0.000 description 1
- 229960000834 vinyl ether Drugs 0.000 description 1
- 238000001429 visible spectrum Methods 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 238000003466 welding Methods 0.000 description 1
- 238000005491 wire drawing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/24—Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body
- A61F2/2442—Annuloplasty rings or inserts for correcting the valve shape; Implants for improving the function of a native heart valve
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/24—Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body
- A61F2/2442—Annuloplasty rings or inserts for correcting the valve shape; Implants for improving the function of a native heart valve
- A61F2/2466—Delivery devices therefor
Landscapes
- Health & Medical Sciences (AREA)
- Cardiology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Prostheses (AREA)
Abstract
The present invention provides a kind of heart valve prosthesis and its fillable structures, the heart valve prosthesis includes: circlecuf, it has the inner surface for limiting blood flow path, and one end of circlecuf is equipped with proximal annular rim pipeline, and the other end of circlecuf is equipped with distal annular rim pipeline;Valve, it is positioned in blood flow path and is connected to circlecuf, valve can allow for the distally flowing in the direction of circulating line direction proximal annular rim pipeline in blood flow path, and prevent the flowing in blood flow path along the direction of the distally directed circulating line of proximal annular rim pipeline;It is connected to the fillable structure of circlecuf, with proximal end ring cavity and distal end ring cavity, proximal annular rim duct wraps proximal end ring cavity, distal annular rim duct wraps distal end ring cavity;Proximal end ring cavity has the trend to contract, to reduce the perimeter of the outer profile of proximal end ring cavity.
Description
Technical field
The present invention relates to the field of medical instrument technology more particularly to a kind of heart valve prosthesis and its fillable structures.
Background technique
Aortic stenosis (Aortic stenosis, abbreviation AS) is common cardiovascular pathological changes, and disease incidence is with the age
Growth and gradually increase.Once there is symptom in AS patient, and prognosis is very poor, if intervening not in time, patient's median survival interval be 2~
3 years.
Surgery aortic valve replacement (Surgery Aortic Valve Replacement, abbreviation SAVR) is that treatment has
The standard regimens of the serious AS patient of indication.However, advanced age is high with the patients surgery risk of complication, it is postoperative extensive
It is multiple slow.According to statistics, there is 1/3 or more serious AS patient that can not carry out SAVR.
Through conduit aortic valve prosthesis displacement technique (Transcatheter Aortic Valve Replacement, abbreviation
TAVR) or through conduit aorta petal implantation (Transcatheter Aortic Valve Implantation, abbreviation
TAVI) have the advantages that wound is smaller, become the new selection of above-mentioned Case treatment.More and more clinical researches are also being explored
TAVR be suitable in low danger patient a possibility that.Currently, U.S. FDA approved portioned product be used in low danger patient, but examine
The problem of considering durability, if still confirmed to more clinical tests suitable for young patient.
After valve implantation multiple complications may occur for the reason of because of valve designs and surgical procedure, as blood vessel is concurrent
Disease is backflowed, stroke, electrocardio block etc., and probably include following several: (1) vascular complication mainly has with approach art formula
It closes, the vascular complication of common Transfemoral approach and the diameter of sheath are related;(2) bleeding, including approach point of puncture are concurrent
Disease, a left side caused by right ventricle perforation, aorta petal ring breakage, dissecting aneurysm of aorta, stiff guide wire caused by pacemaker wires
Perforation of ventricle etc.;(3) cerebrovascular events, such as cerebral apoplexy, self-expanding valve and valve model it is excessive be thrombosis independent danger
Dangerous factor, expansion after sacculus, valve displacement, valve mesopetalum (TAVI-in-TAVI) are the independent hazard factors of cerebral apoplexy;(4) acute
Injury of kidney, the use that low blood pressure and contrast agent occurs in art when the fragment embolism arteria renalis, rapid pacing is the danger of acute kidney injury
Dangerous factor;(5) aortic regurgitation is divided into centrality and backflows and perivalvular leakage, predominantly perivalvular leakage, and centrality is backflowed and valve is unfolded
Not exclusively related, the factor of perivalvular leakage includes too high or too low position of valve, the calcification of valve placement region, valve size and annulus
Size mismatches;(6) position of valve is abnormal, mostly bad related with releasing position, and reason includes that valve size is improper, expands not
Sufficiently, hypertrophic obstructive cardiomyopathy etc.;(7) coronary artery blockage is often blocked by the leaflet of itself, especially the valve of calcification
Leaf, clinically research shows that coronary artery blockage easily occurs for coronary ostium height ﹤ 10mm;(8) arrhythmia cordis, including chamber
Block and atrial fibrillation, for expanding valve compared to ball, self-expanding valve because having bigger volume and contact area is easier to that room occurs
Room block, serious atrioventricular block need to be implanted into permanent pacemaker.
US7556645B2、US8012201B2、US7435257B2、US7445630B2、US7320704B2、
US7534259B2, US8377118B2 and US20090088836A1 disclose the structure of valve prosthesis, US9603708B2,
CN104602646B and CN106794064A discloses the structure of the transportation system of valve prosthesis.By transportation system, by valve
Prosthese is delivered at native valve, and valve prosthesis substitutes native valve and plays physiological function.Fillable knot is equipped in valve prosthesis
Structure can be filled with filled media by transportation system into fillable structure, or filled media is taken out from fillable structure
Out;Valve prosthesis is made of flexible material, and after filled media is extracted, valve prosthesis, which is in, takes out flat state, can be facilitated
It is conveyed in valve prosthesis.After valve prosthesis reaches accurate location, it is filled with filled media, is fully deployed valve prosthesis
And release.
CN106794064A discloses a kind of aortic valve implant 800 and for conveying aortic valve implant
800 combination transfer system;Aortic valve implant 800 includes fillable structure 813, and combination transfer system includes that conveying is led
Pipe 900.In the aortic valve implantation through femoral artery, in order to enable aortic valve implant 800 heart from
Smoothly it is unfolded at body valve, aortic valve implant 800 must be delivered into first to the left ventricle of human body, into after left ventricle,
By being filled with filled media into fillable structure 813, after test 800 function of aortic valve implant is normal, by proximal end end
Filled media extraction in portion 803, proximal end 803 are to take out flat state, can pull up aortic valve implant 800
To being stuck at the aortic valvular ring of heart.
But in surgical procedure, annulus more severe for aortostenosis is open small patient, by aortic valve
The difficulty that the proximal end of implantation material is pulled through in aortic valvular ring arrival aorta from left ventricle is larger.
Summary of the invention
The object of the present invention is to provide a kind of heart valve prosthesis and its fillable structure, with alleviate in the prior art for
Aortostenosis is more severe, annulus is open small patient, is pulled through aorta petal from left ventricle for the proximal end of aortic valve prosthese
Ring reaches the larger technical problem of the difficulty in aorta.
Following technical proposal can be used to realize in above-mentioned purpose of the invention:
It includes: circlecuf that the present invention, which provides a kind of heart valve prosthesis, has the inner surface for limiting blood flow path, institute
The one end for stating circlecuf is equipped with proximal annular rim pipeline, and the other end of the circlecuf is equipped with distal annular rim pipeline;Valve,
It is positioned in the blood flow path and is connected to the circlecuf, the valve can allow in the blood flow path along described
Distal annular rim pipeline is directed toward the flowing in the direction of the proximal annular rim pipeline, and prevents in the blood flow path along the proximal loop
Shape pipeline is directed toward the flowing in the direction of the distal annular rim pipeline;It is connected to the fillable structure of the circlecuf, is had
Proximal end ring cavity and distal end ring cavity, proximal end ring cavity described in the proximal annular rim duct wraps, described in the distal annular rim duct wraps
Distal end ring cavity;The proximal end ring cavity has the trend to contract, to reduce the perimeter of the outer profile of the proximal end ring cavity.
In a preferred embodiment, the material of the proximal end ring cavity uses elastic material;It is to take out in the proximal end ring cavity
In the case where flat state, the perimeter of the outer profile of the proximal annular rim pipeline is less than the week of the outer profile of the distal annular rim pipeline
It is long.
In a preferred embodiment, the elasticity modulus of the material of the proximal end ring cavity, less than the material of the distal end ring cavity
The elasticity modulus of material.
In a preferred embodiment, under expanded state, the Zhou Changwei L of the outer profile of proximal end ring cavity, diameter D;In
It takes out under flat state, the Zhou Changwei L ' of the outer profile of proximal end ring cavity, diameter is D ';Meet following relationship:
(D/D ') < (L/L ').
In a preferred embodiment, under expanded state the outer profile of proximal end ring cavity perimeter L, it is close in the case where taking out flat state
The perimeter L of the outer profile of end ring chamber ';
Meet following relationship:
150%≤(L/ ')≤500%.
In a preferred embodiment, meet following relationship:
200%≤(L/L ')≤450%.
In a preferred embodiment, meet following relationship:
250%≤(L/L ')≤400%.
In a preferred embodiment, the tolerable burst pressure of the proximal end ring cavity is greater than or equal to 5atm.
In a preferred embodiment, the tolerable burst pressure of the proximal end ring cavity is greater than or equal to 16atm.
In a preferred embodiment, the material of the proximal end ring cavity includes PVC, thermoplastic elastomer (TPE), latex, silicon rubber
In wantonly a kind of monomer or appoint a variety of mixed complexs of more than two kinds.
In a preferred embodiment, the material of the proximal end ring cavity includes Chronoprene or Pebax.
In a preferred embodiment, the proximal annular rim pipeline can prevent the outer profile of the proximal end ring cavity to extending out
.
In a preferred embodiment, the fillable structure include be set to the proximal end ring cavity and the distal end ring cavity it
Between column sections;The proximal end ring cavity and the leg portion are split into type, and are fixed in together.
In a preferred embodiment, the heart valve prosthesis is adapted with aortic valvular ring.
The present invention provides a kind of fillable structure of heart valve prosthesis, applied to above-mentioned heart valve prosthesis, comprising:
Proximal end ring cavity, distal end ring cavity and the column sections between the proximal end ring cavity and the distal end ring cavity;The proximal end ring cavity
Material uses elastic material, so that the proximal end ring cavity is had the trend to contract, to reduce the outer profile of the proximal end ring cavity
Perimeter.
The features of the present invention and advantage are:
It, can be first by filling out in proximal loop chamber when heart valve prosthesis provided by the invention is moved from left ventricle to aorta
Filling medium extraction, proximal end ring cavity lose the supporting role of filled media, and the material of proximal end ring cavity uses elastic material, makes proximal loop
Chamber has the trend to contract, and since proximal end ring cavity is lived by proximal annular rim duct wraps, proximal end ring cavity and proximal annular rim
Pipeline can be together to contract, and the perimeter of the outer profile of proximal annular rim pipeline reduces, so that the proximal end of the heart valve prosthesis is contracted
It is small, reduce the obstruction that the proximal end of the heart valve prosthesis is subject to when passing through primary aortic valvular ring, is conducive to the heart
The proximal end of valve prosthesis successfully moves to side of the aortic valvular ring far from left ventricle, reduces conveying difficulty.
After the heart valve prosthesis reaches accurate location, it is filled with filled media into fillable structure, proximal end ring cavity and remote
End ring chamber reaches expanded state, and proximal end ring cavity applies the active force expanded outwardly to proximal annular rim pipeline, overcomes proximal annular rim
To the trend of contract, circlecuf and aortic valvular ring formation cooperation, heart valve prosthesis realization are fully deployed pipeline.
Heart valve prosthesis provided by the invention has preferably recyclable, relocatable performance, and anti-perivalvular leakage effect is good,
It is readily delivered and discharges, can be accurately positioned, convenient for operation, be conveniently adjusted to the direction with heart and keep alignment, it is compressible
Property it is high, blood vessel can be effectively reduced and disease occurs, blocking coronary artery is reduced and cause the probability of electrocardio block, and nothing
Anti-coagulants need to be used throughout one's life, is more suitable for aortostenosis patient, keep clinical manipulation more convenient.
Detailed description of the invention
To describe the technical solutions in the embodiments of the present invention more clearly, make required in being described below to embodiment
Attached drawing is briefly described, it should be apparent that, drawings in the following description are only some embodiments of the invention, for
For those of ordinary skill in the art, without creative efforts, it can also be obtained according to these attached drawings other
Attached drawing.
Fig. 1 is the schematic cross-section of heart and its Major Vessels;
Fig. 2 is that heart valve prosthesis provided by the invention is placed in the cross-sectional view at aortic valvular ring;
Fig. 3 A is a kind of structural schematic diagram of transportation system;
Fig. 3 B is the schematic diagram that heart valve prosthesis provided by the invention is connected to transportation system shown in Fig. 3 A;
Fig. 3 C is the structural schematic diagram of the PFL pipeline in transportation system shown in Fig. 3 A;
Fig. 3 D be Fig. 3 A in A-A to cross-sectional view;
Fig. 4 A- Fig. 4 C is a kind of the partially unfolded schematic diagram with each step in position fixing process of heart valve prosthesis;
Fig. 5 A- Fig. 5 E is the schematic diagram of each step during a kind of expansion of heart valve prosthesis, test and repositioning;
Fig. 6 A is a kind of structural schematic diagram of heart valve prosthesis in the case where taking out flat state;
Fig. 6 B is the top view of heart valve prosthesis shown in Fig. 6 A;
Fig. 7 A is the perspective view for inventing the heart valve prosthesis provided under expanded state;
Fig. 7 B is the top view of heart valve prosthesis shown in Fig. 7 A;
Fig. 8 A is the structural schematic diagram for inventing the heart valve prosthesis provided under expanded state;
Fig. 8 B is heart valve prosthesis radial cross-section shown in Fig. 8 A;
Fig. 8 C is the partial enlarged view of upper left quarter in Fig. 8 B;
Fig. 9 is the schematic diagram that structure can be filled in heart valve prosthesis shown in Fig. 8 A;
Figure 10 is the schematic diagram of connectivity port and PFL pipeline;
Figure 11 is that the expansion before fillable structure and circlecuf assembling in the heart valve prosthesis that invention provides is illustrated
Figure;
Figure 12 A is the structural schematic diagram for inventing the heart valve prosthesis provided in the case where taking out flat state;
Figure 12 B is the top view of heart valve prosthesis shown in Figure 12 A;
Figure 13 A is to make the fabric of circlecuf in the first embodiment of heart valve prosthesis provided by the invention to show
It is intended to;
Figure 13 B is to make the fabric of circlecuf in the second embodiment of heart valve prosthesis provided by the invention to show
It is intended to;
Figure 14 A is proximal annular rim pipeline and elastic webbing phase in the third embodiment of heart valve prosthesis provided by the invention
The top view of connection;
Figure 14 B is the front view of Figure 14 A;
Figure 14 C is proximal annular rim pipeline and elastic webbing phase in the 4th embodiment of heart valve prosthesis provided by the invention
The top view of connection;
Figure 14 D is the front view of Figure 14 C;
Signal of the proximal end ring cavity in expanded state in 5th embodiment of Figure 15 A heart valve prosthesis provided by the invention
Figure;
Proximal end ring cavity is in the signal for taking out flat state in 5th embodiment of Figure 15 B heart valve prosthesis provided by the invention
Figure.
Drawing reference numeral explanation:
32, left ventricle;34, aortic valve;36, aorta;
800, heart valve prosthesis;880, the axis of circlecuf;881, the axis direction of circlecuf;882, annular sleeve
The cross-sectional direction of band;
801, folding part;8011, proximal annular rim pipeline;8012, distal annular rim pipeline;
802, circlecuf;8021, weft;8022, warp;8023, cuff waist;
803, the proximal end of heart valve prosthesis;804, the distal end of heart valve prosthesis;805, waist;
812, suture;
813, structure can be filled;806, column sections;807a, proximal end ring cavity;807b, distal end ring cavity;808, filling channel;
809, connectivity port;
810, filling-valve;8101, the first filling-valve;8102, the second filling-valve;
303, ball;304, soft seal;305, stop bulb stopper;312, tubular portion;
811, check valve;
104, valve;1041, built-in edge;1042, free edge;
300, snare;400, elastic webbing;
900, delivery conduit;
901, outer tubular member;902, exterior tube proximal end;903, exterior tube distal end;
904, inner tubular member;905, inner tube proximal end;906, inner tube distal end;911, band is marked;
907, handle;908, outer sheath handle;
912, sheath;913, outer sheath marks band;
914, guide wire canal;915, wire leading pipe tip;
916, PFL pipeline;917, female Luer;918, part is depressurized;919, needle;920, PFL is marked;
921, side ports valve.
Specific embodiment
Following will be combined with the drawings in the embodiments of the present invention, and technical solution in the embodiment of the present invention carries out clear, complete
Site preparation description, it is clear that described embodiments are only a part of the embodiments of the present invention, instead of all the embodiments.It is based on
Embodiment in the present invention, it is obtained by those of ordinary skill in the art without making creative efforts every other
Embodiment shall fall within the protection scope of the present invention.
In order to make heart valve prosthesis provided by the invention it is more readily appreciated that next providing heart and the present invention
Fit system of the heart valve prosthesis in heart briefly introduce, and introduce a kind of transportation system and its delivery method
With a kind of filled media.
Heart
Fig. 1 is the schematic cross-section of heart and its Major Vessels, and Fig. 2 is that heart valve prosthesis provided by the invention is placed in master
Cross-sectional view at artery annulus.When conveying the heart valve prosthesis, the heart valve prosthesis 800 is made to be sent into left ventricle 32 first
In, move the heart valve prosthesis 800 to aorta 36, aorta petal is passed through in the proximal end 803 of the heart valve prosthesis
Ring forms fit structure as shown in Figure 2.
Transportation system
The transportation system is for heart valve prosthesis 800 provided by the invention to be delivered at the aortic valvular ring of heart.
Transportation system includes delivery conduit 900, referring to figure 3. A- Fig. 3 D, and delivery conduit 900 may include from delivery conduit
The elongate flexible catheter body that 900 proximal end extends to the distal end of delivery conduit 900.In some embodiments, catheter body has
About 18Fr (French) or smaller largest outer diameter, and the overall diameter of the distal portions of catheter body (i.e. deploying portion) more
It is small.
Certain features of heart valve prosthesis 800 and delivery conduit 900 convey heart valve for promotion in catheter body
Film prosthese 800 be it is especially advantageous, catheter body has about 18Fr or smaller overall diameter and still maintains the thickness of tissue valve prosthesis
Degree is equal to or greater than about 0.011 inch, and/or, effective orifice area is equal to or greater than about 1 square centimeter or at another
It is equal to or greater than about 1.3 square centimeters in embodiment or is equal to or greater than about 1.5 squares lis in another embodiment
Rice.
In one embodiment, the expansion that can convey heart valve prosthesis 800 across 18F or smaller overall diameter is led
Pipe, and when being filled up completely, the effective orifice area (Effective Orifice Area) of heart valve prosthesis 800 is greater than etc.
In 1.0 square centimeters;In another embodiment, at least about 1.3 square centimeters of effective orifice area;At another
There is about 1.5 square centimeters of effective orifice area in embodiment.In one embodiment, heart valve prosthesis 800 has
There is at least about 1.75 square centimeters of smallest cross-sectional circulation area.
In some embodiments, the overall diameter after heart valve prosthesis 800 is unfolded is greater than or equal to 22mm.Some
In embodiment, connected between catheter body and heart valve prosthesis 800 by PFL pipeline 916.In one embodiment, defeated
Sending system with the seal wire of 0.035 " or 0.038 " is compatible.
Delivery conduit 900 can be constructed with the pipeline squeezed.In some embodiments, delivery conduit 900 can will be compiled
Line knit or coiling and/or silk ribbon are merged into pipeline to provide the hardness and rotation dynamics reinforced.The number of line and/or silk ribbon
Measuring range is 1 to 64.Preferably, the quantitative range of line and/or silk ribbon is 8 to 32.The diameter range of line is 0.0005 English
Very little to about 0.0070 inch.If preferred thickness is less than width, and the thickness range of silk ribbon can be from about using silk ribbon
0.0005 inch to about 0.0070 inch, and width range can be from about 0.0010 inch to about 0.0100 inch.At another
In embodiment, use coil as stiffener, coil may include number be 1 to 8 between line or silk ribbon, they wind
Pipe surrounding and be embedded into pipe.Line can dissipate around, therefore in their plane of bendings parallel to each other and in pipe surface, or
More lines are wound in the opposite direction in separated layer.It can be similar to for the line of coil or the size of silk ribbon for ribbon
Size.
A referring to figure 3., delivery conduit 900 may include the distal end from the proximal end of delivery conduit 900 to delivery conduit 900
The outer tubular member 901 of extension and the inner tubular extended from the proximal end of delivery conduit 900 to the distal end of delivery conduit 900
Component 904;Outer tubular member 901 has exterior tube proximal end 902 and exterior tube distal end 903;Inner tubular member 904 has interior
Portion pipe proximal end 905 and inner tube distal end 906.Inner tubular member 904 can usually extend through outer tubular member 901, because
The inner tube proximal end 905 of this inner tubular member 904 and inner tube distal end 906, extend respectively across outer tubular member 901
Exterior tube proximal end 902 and exterior tube distal end 903.
The exterior tube distal end 903 of outer tubular member 901 may include sheath 912 and backbone area, from sheath 912
Proximally extend.In some embodiments, sheath 912 is made of high molecular material, for example, by using KYNAR pipeline.It please join
According to Fig. 3 A and Fig. 3 B, sheath 912 can accommodate the heart valve prosthesis 800 of contraction state to be transported to implantation position.In
In some embodiments, sheath 912 can propagate at least partly light in visible spectrum.This allows to show heart valve prosthesis
800 orientation in delivery conduit 900.In some embodiments, band 913 can be marked to be placed in outer tubular structure outer sheath
The exterior tube distal end 903 of part 901.
In some embodiments, the backbone area that sheath 912 compares outer tubular member 901 close on or nearside can
With biggish overall diameter.In these embodiments, sheath 912 and backbone area may include separated tube assembly,
They are attached or are otherwise coupled to each other.In other embodiments, outer tubular member 901 can be expanded to be formed
Larger-diameter sheath 912, so that backbone area and sheath 912 are formed by common pipe component, to advantageously reduce trunk region
The diameter in domain.
A referring to figure 3., the inner tube proximal end 905 of inner tubular member 904 are connected to handle 907 relative to exterior tube
Shape component 901 is firmly grasped and mobile inner tubular member 904.The exterior tube proximal end 902 of outer tubular member 901 can be connected to
Outer sheath handle 908 relative to inner tubular member 904 to firmly grasp and keep outer tubular member 901 static.Preferably, outside
Between portion's tubular element 901 and inner tubular member 904, hemostasis seal 909 can be provided, and can be by hemostasis seal
909 configurations are in outer sheath handle 908.In some embodiments, outer sheath handle 908 includes side ports valve 921, and is flowed
Body can flow into outer tubular member by side ports valve 921.
D referring to figure 3., inner tubular member 904 include multi-cavity hypotube.In some embodiments, inner tubular structure
The internally positioned pipe proximal end 905 of cervical part of esophagus 910 of part 904.Cervical part of esophagus 910 can be by stainless steel, Nitinol or other suitable material
Material is made, these materials can be to provide additional strength with inner tubular member mobile in outer tubular member 901
904.In some embodiments, B, label band 911 appear in inner tube distal end 906 referring to figure 3..The wall thickness of multi-cavity hypotube
Spending range is 0.004 inch to 0.006 inch.Preferably, the wall thickness of multi-cavity hypotube is about 0.0055 inch, provides foot
Enough big powers' degree simultaneously increase bend loading needed for hypotube of twisting together.In some embodiments, with reference to Fig. 3 D, inner tubular structure
Part 904 includes at least four chambers, and one in these chambers can accommodate guide wire canal 914, and each of other chambers can be with
It accommodates and places PFL pipeline 916.It can configure guide wire canal 914 to accommodate seal wire.PFL pipeline 916 can be configured to both use
Make to place the control line of heart valve prosthesis 800 in implantation position, and is used as and liquid, gas or filled media are transported to the heart
The filling pipe of dirty valve prosthesis 800.Particularly, PFL pipeline 916 can permit the angular adjustment of heart valve prosthesis 800.Also
It is to say, the valve plane perpendicular to its axis of heart valve prosthesis 800 can be adjusted by PFL pipeline 916, to guarantee the heart
The alignment of dirty valve prosthesis 800 and human body annulus.
A and 3B referring to figure 3., in general, guide wire canal 914 can be longer than and extend through the length of delivery conduit 900.
Due to the control of operator, the proximal end of guide wire canal 914 can pass through inner sheath handle 907;The distal end of guide wire canal 914 can
Exterior tube distal end 903 is extended beyond, and wire leading pipe tip 915 can be connected to.It wire leading pipe tip 915 can be close to exterior tube
Distally 903 and the heart valve prosthesis 800 of retraction is protected, for example, during promoting delivery conduit.By keeping wire leading pipe
To proximal retraction outer tubular member 901 while road 914 is static, wire leading pipe tip 915 may be located remotely from outer tubular member
901.It is alternatively possible to promote guide wire canal 914 while keeping outer tubular member 901 static.Guide wire canal 914 can be with
With about 0.035 inch to about 0.042 inch of interior diameter, therefore, compatible common 0.035 " or 0.038 " of conduit system
Seal wire.In some embodiments, guide wire canal 914 can have about 0.014 inch to about 0.017 inch of interior diameter, because
This, the compatible 0.014 " seal wire of diameter of conduit system.Guide wire canal 914 can be by such as polytetrafluoroethylene (PTFE), polypropylene or use
The lubricious material of the polymer of polytetrafluoroethylene (PTFE) dipping is made.Guide wire canal 914 can also be coated with smooth or hydrophilic coating.
Wire leading pipe tip 915 can be taper, bullet shape or hemispherical in front end.Preferably, wire leading pipe tip 915
The diameter of maximum gauge and exterior tube distal end 903 it is approximately uniform.Preferably, wire leading pipe tip 915 reduces diameter to slightly smaller than
The inside diameter of outer sheath 912, therefore tip can engage outer sheath 912 and provide smooth transition.Guide wire canal 914
Front end is wrapped up the front end at through wire leading pipe tip 915 by wire leading pipe tip 915, can be inserted into and lead from 914 end of guide wire canal
Wire leading pipe tip 915 is connected to guide wire canal 914, and lead in example embodiment through wire leading pipe tip 915 by silk
Silk chamber (guidewire lumen) passes through the part at wire leading pipe tip 915.The proximal side at wire leading pipe tip 915 also have taper,
Bullet shaped or hemispherical retract wire leading pipe tip 915 easily across expansion heart valve prosthesis 800, and into
Enter conduit is unfolded, in this way, to recession wire leading pipe tip 915, when into delivery conduit, being not easy and heart valve prosthesis after implantation
It is tangled between 800.It wire leading pipe tip 915 can be flexible by the rigid polymer of such as polycarbonate, or by allowing
It is manufactured compared with low-durometer material such as silica gel.Optionally, wire leading pipe tip 915 can be by the multiple material system with different hardness
At.For example, the part of the engagement exterior tube distal end 903 at wire leading pipe tip 915 can be by rigid material, and wire leading pipe tip
915 distal end and/or proximal end can be made of the material compared with soft.
Further, it is configured to wire leading pipe tip 915 to be inserted directly into blood vessel along seal wire.It in this way, can be with
Using the blood vessel that wire leading pipe tip 915 and sheath 912 directly expand into accommodate the inducting device positioned along delivery conduit
Conduit.
Each PFL pipeline 916 can extend in the whole length of delivery conduit 900.The proximal end of PFL pipeline 916 passes through
Handle 907, and have female Luer 917 with connecting fluid, gas or filled media source.The distal end of PFL pipeline 916 passes through
Hypo lumen extends beyond the inner tube distal end 906 of inner tubular member 904.With reference to Fig. 3 C, in some embodiments, PFL
Pipeline 916 includes decompression part 918 in the proximal end for being connected to female Luer 917, and when being manipulated by operator, depressurizes part
918 to mitigate the tension on PFL pipeline 916.The distal end of PFL pipeline 916 includes tip or needle 919 to be connected to heart valve
Prosthese 800.In some embodiments, one end of needle 919 has threaded portion.In some embodiments, PFL pipeline 916
Distal end and/or proximal end can have PFL label 920, with for identification.
In some embodiments, PFL pipeline 916 is designed as adapting to being easy rotation in bending anatomical structure.It can be with
PFL pipeline 916 is constructed using polyimides woven tube, Nitinol hypotube or stainless steel hypotube.Preferably, PFL pipeline
916 polyimides by weaving is made, and is made of the polyimides liner being woven by flat wire, by another polyimide layer
Encapsulate and use polyether-block-polyamide and nylon outer layer jacket;Specifically, polyether-block-polyamide uses Pebax.In some realities
It applies in mode, Nitinol casing can be added to the proximal end of PFL pipeline 916 to improve torque drive, kink resistance and push away
Power.In some embodiments it is possible to coat outer surface and/or the multi-cavity of PFL pipeline 916 using smooth silica-gel coating
The inner surface of chamber in hypotube is to reduce friction.In some embodiments, on the inner surface of the chamber in multi-cavity hypotube
The interior lining material of such as polytetrafluoroethylene (PTFE) can be used to reduce friction and improve the performance in bending.Alternatively, it is also possible to
The nonskid coating or hydrophilic coating of such as silicone oil or MDX silica gel is added to provide another form of reduction friction element;It is excellent
Selection of land, silicone oil use DOW360.During placing heart valve prosthesis 800, this can provide the accurate control of PFL pipeline 916.
It in some embodiments, can be by the outer surface jacket of PFL pipeline 916 and with other nylon 12 or Rilsan AESNO
Layer flows back to ensure the surface of smooth exquisiteness.In some embodiments it is possible to which anti-thrombogenic coatings are put into PFL pipeline 916
Outer surface on to reduce thrombosed risk on pipeline.
In some embodiments, the overall diameter range of delivery conduit 900 is 0.030 inch to 0.200 inch, exterior tube
The wall range of shape component 901 is 0.005 inch to 0.060 inch.In some embodiments, outer tubular member 901
Overall diameter can be about between 0.215 inch and about 0.219 inch.In this embodiment, the wall of outer tubular member 901
With a thickness of between about 0.005 inch and about 0.030 inch.The overall length range of delivery conduit 900 is from about 80 centimetres to about 320
Centimetre.In some embodiments, the active length of outer tubular member 901 is (from the distal end of sheath 912 to outer tubular member
901 are connected to the position of outer sheath handle 908) it can be about 100cm to about 120cm.In some embodiments, sheath 912
Interior diameter can greater than or equal to about 0.218 inch, and the overall diameter of sheath 912 be less than or equal to about 0.241 inch.In
In preferred embodiment, the overall diameter of sheath 912 can be for less than or equal to about 0.236 inch or 18Fr.In some implementations
In mode, the overall diameter of PFL pipeline 916 can be for less than or equal to about 0.0435 inch, and length is about 140cm to 160cm.
Preferably, the heart valve prosthesis 800 under contraction state fits into sheath 912.Sheath 912 can have 18Fr
Or smaller overall diameter.
The heart valve prosthesis 800 of retraction is usually loaded between exterior tube distal end 903 and inner tube distal end 906.Cause
This, exterior tube distal end 903 can form the container of heart valve prosthesis 800.By being kept when outer tubular member 901 is shunk
It is static to control heart valve prosthesis 800, it can heart valve prosthesis 800 is exposed or containers for pushing out.Optionally, outer tubular structure
Part 901 can be remain stationary when promoting inner tubular member 904, thus by 800 containers for pushing out of heart valve prosthesis.
Delivery method
Above-mentioned transportation system can use the delivery method, and heart valve prosthesis provided by the invention is delivered to heart
At aortic valvular ring.
In clinical application, first by seal wire insertion body, then the lumen alignment seal wire of guide wire canal 914 pushed away in human body
It send, entire transportation system enters in vivo along seal wire, and seal wire plays a part of guiding.Referring to figure 3. shown in B, heart will be carried
900 intravascular of delivery conduit of valve prosthesis 800 promotes.In some embodiments, delivery conduit 900 is inserted along seal wire
Enter.In these embodiments, wire leading pipe tip 915 can be inserted directly into blood vessel along seal wire.In some embodiments,
Delivery conduit 900 is promoted to reach patient until outer sheath handle 908.In other embodiments, it leads when being pushed further into conveying
When pipe 900, delivery conduit 900 can be advanced to the position close to native valve.
In other embodiments, it may be necessary to cooperate inducting device conduit, inducting device conduit is led for establishing blood vessel approach
Enter device conduit to be used in combination with delivery conduit 900.
In some embodiments, by partially or even wholly being received while keeping inner tubular member 904 static
Outer tubular member 901 is returned, can appear or expose heart valve prosthesis 800, and is allowed at native valve or native valve
Under appropriate placement.In some embodiments it is possible to by while keeping outer tubular member 901 static to remote
Side pushes inner tubular member 904 to appear heart valve prosthesis.Once heart valve prosthesis 800 is pulled out, so that it may Xiang Jin
Side is distally moved heart valve prosthesis 800, and fluid or filled media can be introduced to fillable structure 813 to provide
Shape and structural intergrity.In some embodiments, distal end ring cavity 807b can be filled with the first liquid first, and
Using the connector between heart valve prosthesis 800 and delivery conduit 900, heart valve prosthesis 800 is placed on implantation position.In
In some embodiments, occur being no more than three connectors.In some embodiments, connector is PFL pipeline 916, can
To be used to control heart valve prosthesis 800 and fill fillable structure 813.
By being detachably connected to the PFL pipeline 916 of heart valve prosthesis 800, heart valve prosthesis 800 can control
Expansion.PFL pipeline 916 is attached to heart valve prosthesis 800, enables heart valve prosthesis 800 from delivery conduit
It is controlled and is placed after 900 taking-ups.Preferably, using three PFL pipelines 916, during expansion and placement, PFL pipeline 916
It is capable of providing the accurate control of heart valve prosthesis 800.PFL pipeline 916 can be used to make heart valve prosthesis 800 to nearside
It is mobile with distal side, or tilt heart valve prosthesis 800 and change its angle relative to native anatomical structure, to be conducive to
Adjust the alignment of heart valve prosthesis 800 and heart.
In some embodiments, heart valve prosthesis 800 includes multiple filling-valves 810 to allow operator with not same amount
Or the fluid or gas of pressure are filled to the specific region of heart valve prosthesis 800.
With reference to Fig. 4 A- Fig. 4 C, in some embodiments, the initial part in left ventricle 32 by heart valve prosthesis 800
(Fig. 4 A) is unfolded in ground.It is partially filled with filling channel 808, allows the distal end ring cavity 807b of heart valve prosthesis 800 to be opened to close
Its entire diameter, and proximal end ring cavity 807a is in unfilled state.Then, heart valve prosthesis is returned to aorta petal
The position of 34 ring of film is neighbouring (Fig. 4 B).In some embodiments, firstly, distal end ring cavity 807b is at least partly filled, so
Afterwards, to proximal retraction heart valve prosthesis 800 to cross over aortic valve 34.Distal end ring cavity 807b is located at the ventricle of aortic annulus
Side, and the surface for 34 ring of aortic valve heart valve prosthesis 800 being placed in aortic root in itself.At this point, PFL
Pipeline 916 can be similar to that Cutting balloon cracks fiber or the same mechanism of calcification lesion helps to separate fusion by mobile
Commissure enables PFL pipeline 916 to cut the part of tissue fusion open by moving.Other filling streams can be added
Body or gas are so that heart valve prosthesis 800 is filled up completely, so that heart valve prosthesis 800 extends across native valve annulus, from
And extend slightly into two sides (with reference to Fig. 4 C).PFL pipeline 916 provides the handle and heart valve prosthesis 800 in delivery conduit 900
Between transmission force mechanism.It, can be along nearside by moving together all PFL pipeline 916 or inner tubular member 904
Direction or distal direction promote or retract heart valve prosthesis 800.By only promoting PFL pipeline relative to other PFL pipelines 916
916 a part, can be relative to the angle and direction of native anatomical structural adjustment heart valve prosthesis 800.When operator is put
When setting and orienting heart valve prosthesis 800, radiopaque on heart valve prosthesis 800 or on PFL pipeline 916 label,
Or the radiopacity of PFL pipeline 916 itself, it can help to indicate 800 direction of heart valve prosthesis.
In some embodiments, heart valve prosthesis 800 has two fillings positioned at every one end of filling channel 808
Valve 810 and the check valve 811 in filling channel 808.Check valve 811 is set, so that fluid or gas can proximally rings
The side of chamber 807a to distal end ring cavity 807b flow up.In some embodiments, it is connected to distal end ring cavity 807b when being attached to
The second filling-valve 8102 pressure charging pump close when, by the first filling-valve 8101 for being attached to and leading to proximal end ring cavity 807a
The pressure charging pump of first PFL pipeline 916 of connection is pressurizeed, and heart valve prosthesis 800 is filled up completely.Fluid or gas can be through
It crosses check valve 811 and flows into distal end ring cavity 807b.Then, by being depressurized to the pressure charging pump for being attached to the second filling-valve 8102, make close
End ring chamber 807a loses heart.Because fluid or gas cannot pass through the leakage of check valve 811, distal end ring cavity 807b will keep filling
State.Then, heart valve prosthesis 800 is placed across self annulus.Once it obtains in satisfactory placement, then it can be right again
Proximal end ring cavity 807a filling.
In some embodiments, heart valve prosthesis 800 can only have a filling-valve 810.
When being filled with fluid or gas to filling channel 808, by dividing while distal part is more completely expanded
Every PFL pipeline 916, the proximal part of heart valve prosthesis 800 can be slightly limited.In general, PFL pipeline 916 limits heart valve
The amount of the proximal diameter of prosthese 800 depends on extending beyond the length of the PFL pipeline 916 of outer tubular member 901, can be by
Operator's adjustment.In other embodiments, burst disk or current limiter can be used to control 800 proximal end of heart valve prosthesis
Partial filling.
After initial deployment, in order to further adjust, heart valve prosthesis 800 can also be made to lose heart or partially lose heart.
As shown in Figure 5A, can with the partially unfolded heart valve prosthesis 800 and using PFL pipeline 916 make heart valve prosthesis 800 against
Aortic valve 34 is placed.It is then possible to which as shown in Figure 5 B is fully deployed heart valve prosthesis 800, then, such as Fig. 4 C institute
That shows test.If test passes through, heart valve prosthesis 800 can be deflated and as shown in Figure 5 D be moved to more excellent position
It sets.Then, heart valve prosthesis 800 can be made to be fully deployed and discharge in slave PFL pipeline 916 as shown in fig. 5e.
In some embodiments, can be formed in vivo by hardenable the filled media of more permanent support construction Lai
Replace above-mentioned fluid or gas.Once operator is satisfied to the position of heart valve prosthesis 800, then then PFL pipeline 916 is broken
It opens, and takes out conduit, leave subsequent heart valve prosthesis 800 (referring to Fig. 5 E) and hardenable filled media.Allow to fill out
Filling medium solidifies in fillable structure 813.Disconnection method may include cutting attachment, rotary screw, taking-up or cutting
The fused combination of needle, mechanical decoupling interlock assembly, electric power separation removes limited cylinder from pipe, comminution engineering area, takes out collet
Device is to show others method known to mechanical splice or the industry.In the embodiment of modification, these steps can be with
It is reverse or according to requiring to modify their sequence.
Preferably, seal wire is exited at least 5 degree and with the angle between 10 degree and 40 degree and is led from transportation system axis direction
The distal tip of silk.This allows delivery conduit 900 to rotate seal wire to be pointing directly at aortic valve to allow to pass through seal wire
Easily cross valve.In one embodiment, the shape at tip and the coronary artery commonly used in crossing aortic valve
The shape of guiding catheter is similar.
In another embodiment, tip is that bending can turn to and tip can be selected by operator.One
In a embodiment, this is completed by using wire drawing.
In some embodiments, including manipulating seal wire as accessory.
The above method essentially describes the embodiment of aortic valve replacement.It is also possible, however, to use similar or modification
Method replace cusps of pulmonary valve or mitral valve or tricuspid.For example, can by venous system or pass through stock it is quiet
Any one of arteries and veins or jugular vein are close to cusps of pulmonary valve.By above-mentioned venous system, can be close to mitral valve, then from
Atrium dextrum by a manner of the diaphragm (trans-sptaly) close to atrium sinistrum.Optionally, as being directed to described in aortic valve,
Conduit can in addition can be used across aortic valve, return to two points then up by arterial system close to mitral valve
Valve.
Filled media
The filled media can be used in being filled the fillable structure in heart valve prosthesis provided by the invention.
Depending on required performance, any different filled media can be used to fill for fillable structure 813.It is logical
Often, filled media may include the liquid or group water solution, such as CO of such as water2Gas or hardenable medium, this can
Hardening medium can be introduced into filling channel 808 with relatively low viscosity and be transformed into relatively high viscosity.It can pass through
Polymerization reaction caused by ultraviolet light or any different known catalyst or other chemical systems known in the art can be with
Complete the enhancing of viscosity.Depending on the performance and durability of requirement, the end point of sticky enhancing process can be from gel to rigid
The hardness of any state of property structure.
Useful filled media those of generally includes to be mixed to form medium, and its solidification by multiple ingredients
Time range is from dozens of minutes by about one hour, preferably from about 20 minutes to about one hour.These materials can be biology
It is compatible, show long-time stability (preferably at least about 10 years in vivo), cause embolic risk as small as possible, before solidification and
Suitable mechanical attributes are all shown after solidification, are suitable for the service of circlecuf 802 in vivo.For example, these materials are solidifying
Gu or should have relatively low viscosity before solidifying to facilitate the filling process of filling channel 808.The solidification of these filled medias
Coefficient of elasticity range is from 50psi to 400psi, in the same of the clinically relevant kink resistance for maintaining circlecuf 802 afterwards
When, balance the needs that fillable structure 813 forms enough sealings in vivo.Ideal filled media should be short-term and long-term all
It is radiopaque, although this is not absolutely required.
One preferred hardenable filled media family is bicomponent epoxy resin.First part is comprising the first aromatics two
The epoxy resin blend of epoxide and the second aliphatic di-epoxy compounds.First aromatics di-epoxy compounds is in water ring
Good mechanically and chemically stability is provided in border, and when in conjunction with aliphatic epoxy resin, it is soluble in aqueous solution.
In some embodiments, the first aromatics di-epoxy compounds includes at least one N, N- diglycidylaniline (N, N-
Diglycidylaniline) base or segment.In some embodiments, the first aromatics di-epoxy compounds is optionally to take
The N in generation, N- diglycidylaniline, substituent group can be oxidation glycidol or N, N- diglycidylaniline base-
Methyl (N, N-diglycidylanilinyl-methyl).The example of unrestricted first aromatics di-epoxy compounds is N, N- bis-
Glycidyl aniline, N, N- diglycidyl -4- glycidol oxo aniline (N, N-diclycidyl-4-
Glycidyloxyaniline (DGO)) and 4,4 '-di-2-ethylhexylphosphine oxides (N, N- diglycidylaniline) (MBD) etc..
Second aliphatic di-epoxy compounds provides low viscosity and good solubility in aqueous solution.Some
In embodiment, the second aliphatic di-epoxy compounds can be 1,3-butadiene dicyclic oxide, glycidol ether or C1-
5 alkane glycol glycidol ethers.The example of unrestricted second aliphatic di-epoxy compounds is 1,3- butadiene, the shrink of butanediol two
Glycerin ether (BDGE), 1,2- ethylene glycol diglycidylether, glycidol ether etc..
In some embodiments, other third compounds can be added to first part's epoxy resin blend to mention
High mechanical attributes and chemical resistance.In some embodiments, which can be aromatic epoxy resin
Rather than contain N, one kind of N- diglycidylaniline.However, the concentration with aromatic epoxy resin increases, asphalt mixtures modified by epoxy resin
The dissolubility of resin blends also can reduce and viscosity can increase.Preferred third compound can be leucoaurin (4- hydroxyl
Phenyl) triglycidyl ether (THTGE), bisphenol A diglycidyl ether (BADGE), Bisphenol F diglycidyl ether (BFDGE) or
Person's resorcinolformaldehyde resin (RDGE).
In some embodiments, other third compounds can be alicyclic epoxide compound, than the first aromatics two
Epoxide is preferably more solvable.It can be than the increase mechanical attributes and change of above-mentioned aromatic epoxy resin smaller extent
Resistance is learned, but it will not reduce solubility as much.The unrestricted example of this cycloaliphatic epoxy resin is 1,4-
Cyclohexanedimethanol divinyl ether (1,4-cyclohexanedimethanol diclycidyl ether) and cyclohexene oxide
1,2- cyclohexane cyclohexanedimethanodibasic 2-glycidyl ester (cyclohexeneoxidediglycidyl1,2-
cyclohexanedicarboxylate).In some embodiments, because of identical reason, can increase tool there are three or
The more aliphatic epoxy resin of polyglycidyl ether group, such as glycidol ether, as other third compounds.Glycidol
Ether, which can increase, to be crosslinked and therefore enhances mechanical attributes.
In general, as the first aromatics di-epoxy compounds concentration increases, the dissolubility of epoxy resin blend reduce and
Viscosity increases.In addition, the concentration with aliphatic di-epoxy compounds in epoxy resin blend increases, mechanical category can be reduced
Property and chemical resistance.By adjusting the ratio of the first aromatics di-epoxy compounds and the second aliphatic di-epoxy compounds, ability
The technical staff in domain can control the attribute of the requirement of epoxy resin blend and hardening media.In some embodiments,
Third compound, which is added, can permit the attribute of further adjustment epoxy resin.
The second part of hardenable filled media includes the curing agent containing at least one aliphatic cyclic amine.It provides reaction
The good combination of property, mechanical attributes and chemical resistance.Aliphatic cyclic amine may include, but be not limited to, isophorone diamine
(IPDA), the bis- aminocyclohexanes of 1,3- (1,3-BAC), diaminocyclohexane (DACH), N- aminoethyl piperazine (AEP) or positive ammonia
Ethyl piperazidine (APP).
In some embodiments, aliphatic amine can be added to second part to increase reactivity, but can be reduced
Mechanical attributes and chemical resistance.Preferred aliphatic amine has following chemical structural formula:
Wherein, each R is selected independently from C2-5 alkyl branches or linear chain, preferably C2 alkyl.Art used herein
Language " alkyl (alkyl) " refers to fully saturated hydrocarbon, including but not limited to, methyl, ethyl group, n- propyl, isopropyl (or i- third
Base), n- butyl, isobutyl group, three-level butyl (or t- butyl), n- hexyl and the like atomic group.For example, being used herein as
Term " alkyl (alkyl) " include the fully saturated hydrocarbon determined by following molecular formula CnH2n+2.In some embodiments,
Aliphatic amine can include but is not limited to four sub- five amine (TEPA), diethylenetriamine and triethylene tetramine.In some embodiments
In, curing agent may further include at least one radiopaque compound, such as iodobenzoic acid.
A kind of specific bi-component medium is listed below.This medium includes:
First part-epoxy resin blend
(1) N, N- diglycidyl -4- glycidol oxo aniline (DGO), with proportional region from about 10 to about 70
Weight percent is presented;Particularly, it is presented with the ratio of about 50 weight percent, (2) butanediol diglycidyl ether
(BDGE) it is presented with proportional region from about 30 to 75 weight percent;Particularly, it is presented with the ratio of about 50 weight percent, and
And optionally, (3) 1,1,4-CHDM divinyl ether, the proportional region with from about 0 to about 50 weight percent is in
It is existing.
Second part-amine hardener
(1) isophorone diamine (IPDA) is presented with the weight percent of proportional region from about 75 to about 100, and can
Selection of land, (2) diethylenetriamine (DETA) are presented with the weight percent of proportional region from about 0 to about 25.
Preferably, the uncured filled media of mixing has the viscosity less than 2000cps.In one embodiment, base
There is the viscosity of 100-200cps in the filled media of epoxy.In another embodiment, filled media has small
In the viscosity of l000cps.In some embodiments, epoxy mixture has the initial viscosity less than about 50cps, or
It is less than about 30cps after person's mixing.In some embodiments, it mixes 10 minutes that the ingredient of two kinds of filled medias starts later
Interior, average viscosity is about 50cps to about 60cps.Low viscosity ensures to convey by the filled cavity of minor diameter expansion conduit
Filled media, the conduit of such as 18Fr.
In some embodiments, filling channel 808 can be connected to PFL pipeline 916 at both ends.This allows with such as
The non-condensable material of gas or liquid carrys out pre-filled filling channel 808, if selection gas, CO2It is preferably to select with helium.It is excellent
Selection of land, pre-fill filling medium be it is radiopaque, can be determined by angiography.It can be used in interventional cardiology and commonly use
Contrast medium to increase sufficient radiopacity for most of liquid pre-fill filling medium.When needing to make heart valve prosthesis 800
When being permanently present and being permanent filled media by pre-filled Medium Exchange, permanent filled media is connected by the first conduit
It connects and is injected into filling channel.In some embodiments, permanent filled media can be frozen into semisolid, gel or solid-state.
Because permanent filled media is introduced into fillable structure 813, pre-fill filling medium is evicted from from the connection of the second conduit.With introducing
Permanent filled media, essentially all of pre-fill filling medium will be all expelled out of.In one embodiment, centre can be used
Filled media to prevent retention of the pre-filled medium in permanent filled media.In one embodiment, intermediate to fill out
Filling medium is gas and pre-fill filling medium is liquid.In another embodiment, intermediate filled media or pre-filled Jie
Matter can be used as primer (primer) to assist permanent filled media to be bonded to the inner surface of filling channel.In another implementation
In mode, pre-fill filling medium or central filler medium prevent permanent filled media to be bonded to filling channel as release agent
Inner surface.
Compared to pre-fill filling medium, permanent filled media can have different radiopacities.It is extremely radiopaque
Device tends to cover the feature near other under angiography.During pre-filling step, clearly show filling channel 808
It may be desired, it is thereby possible to select very radiopaque filled media.When with permanent filled media be device filling
Afterwards, less radiopaque filled media may be preferred.When contrast medium is injected into ventricle or aorta, less ray
The feature of impermeability is beneficial for the visualization of normal valve function.
Filled media, transportation system and delivery method are introduced above.
In the aortic valve implantation through femoral artery, heart valve prosthesis 800 be loaded into delivery conduit 900 it
Before, heart valve prosthesis 800 is to take out flat state, and fold when loading in an inclined angle, heart valve prosthesis 800
Folded length is greater than the height after heart valve prosthesis 800 is unfolded, and folded cross-sectional profiles is reduced, so as to minimum
Compression volume be loaded into the sheath of 900 front end of delivery conduit, reduce delivery conduit 900 conduit cross-sectional facial contour, so as to
Smooth intravascular delivers into heart, facilitates through lesser blood vessel or have the blood vessel of vascular lesion, reduces blood vessel simultaneously
Send out the generation of disease.
After heart valve prosthesis 800 is delivered into human body by delivery conduit 900, the reason of because of above-mentioned oblique fold,
It can not smoothly be unfolded at the primary annulus of heart, heart valve prosthesis 800 must be delivered into first to the left ventricle of human body, enter
After left ventricle, by injecting filled media in the filling channel 808 to heart valve prosthesis 800, heart valve prosthesis 800 is tested
After function is errorless, heart valve prosthesis 800 can be brought up at the aortic valvular ring of heart.
After testing, being vacuumized in the end of filling channel 808, then the part of 811 or more check valve can be taken out flat,
That is proximal end ring cavity 807a and partial column sections 806 are flat by pumping, and the distal end ring cavity 807b for being located at 811 downstream of check valve is then kept
Expanded state.It, can be by the reduced cross-sectional area of proximal loop chamber 807a, in order to by primary annulus, by heart by drawing
Valve prosthesis 800 is placed between left ventricle and aorta efferent tract, then passes through the proximal end ring cavity to heart valve prosthesis 800
Filled media is filled in 807a, heart valve prosthesis 800 is fully deployed, the subsequent behaviour for carrying out the release of heart valve prosthesis 800
Make.
Fig. 4 A- Fig. 4 C shows the proximal end ring cavity 807a of heart valve prosthesis 800 in the case where taking out flat state, by PFL pipeline 916
The form schematic diagram of drawing.Proximal end ring cavity 807a is thin unformed state, when being pulled by PFL pipeline 916, proximal end ring cavity
There is certain diminution in the cross section of 807a, less than the cross section of distal end ring cavity 807b, still, relative to aortic valvular ring, proximal end
The cross section of ring cavity 807a is still larger, by when still will receive biggish obstruction.There may be the aorta because of patient
Valve excessively narrow or two valves or calcification are serious and increase the difficulty of operation.
In order to alleviate the above problem, following two mode can be used:
(1) when operating in vivo, the PFL pipeline 916 that 3 are connected with heart valve prosthesis 800 is pulled back into conveying
In the outer tubular member 901 of conduit 900, between the part that the distal end of 3 PFL pipelines 916 is connected with heart valve prosthesis 800
Distance reduce, drive reduce heart valve prosthesis 800 proximal end ring cavity 807a outer profile.But because heart valve prosthesis
800 in vivo, can not intuitively observe the range of proximal end ring cavity 807a diminution, increases difficulty for operation, and pull delivery system
System will increase contact of the transportation system with blood vessel, increase the risk of potential injury of blood vessel.
(2) 3 PFL pipelines 916 are successively pulled, so that the different piece on the ring cavity 807a of proximal end passes sequentially through aorta
Valve increases the operating time although slightly reducing across the difficulty of annulus in this way, namely increases blood residence time, shadow
The blood circulation for ringing patient, increases the risks such as kidney injury.
But inventors have found that only relying on by means of traction action, unformed loose proximal end ring cavity 807a's reduces the scope very
It is limited., annulus more severe for aortostenosis is open small patient, and the proximal end 803 of heart valve prosthesis is drawn and arrives aorta
There may be bigger difficulty in efferent tract.
Thus, inventor improves heart valve prosthesis 800, to alleviate in the prior art, for aortostenosis
More severe, annulus is open small patient, and the proximal end of aortic valve prosthese is pulled through to aortic valvular ring entrance from left ventricle 32
The larger technical problem of the difficulty of aorta.
Following description will be carried out mainly under the background for replacing or repairing abnormal or illness aortic valve 34.
However, the skill personnel of this field will be appreciated that the various features of method disclosed herein and structure can answer according to disclosure herein
For replacing or repairing heart mitral valve, cusps of pulmonary valve and/or tricuspid.In addition, those skilled in the art also will
It recognizes, the various features of method disclosed herein and structure, which also can be used, contains valve or can from valve in body
Increase in the other parts be benefited, such as oesophagus, stomach, urinary catheter and/or bubble, bile pipe, lymphatic system and enteron aisle;Example
Such as, hook is added, to be adapted with bicuspid valve.
Heart valve prosthesis
The present invention provides a kind of heart valve prosthesis, as shown in Fig. 7 A, Fig. 7 B and Fig. 8 A, the heart valve prosthesis 800
It include: circlecuf 802, valve 104 and the fillable structure 813 for being connected to circlecuf 802;Circlecuf 802 has limit
Determine the inner surface of blood flow path, one end of circlecuf 802 is equipped with proximal annular rim pipeline 8011, the other end of circlecuf 802
Equipped with distal annular rim pipeline 8012;Valve 104 is positioned in blood flow path and is connected to circlecuf 802, and valve 104 can be permitted
Perhaps distally circulating line 8012 is directed toward the flowing in the direction of proximal annular rim pipeline 8011 in blood flow path, and prevents blood flow path
The flowing in the interior direction along the distally directed circulating line 8012 of proximal annular rim pipeline 8011;Fillable structure 813 has proximal loop
Chamber 807a and distal end ring cavity 807b, proximal annular rim pipeline 8011 wrap up proximal end ring cavity 807a, and distal annular rim pipeline 8012 wraps up far
End ring chamber 807b;Proximal annular rim pipeline 8011 has the trend to contract, to reduce the outer profile of proximal annular rim pipeline 8011
Perimeter.
It, can first will be in proximal loop chamber 807a when the heart valve prosthesis 800 is moved from left ventricle 32 to aorta 36
Filled media extraction, proximal end ring cavity 807a loses the supporting role of filled media, since proximal end ring cavity 807a is by proximal annular rim pipe
Road 8011 wraps, proximal end ring cavity 807a and proximal annular rim pipeline 8011 can together to contract, proximal annular rim pipeline 8011
The perimeter of outer profile reduces, so that the proximal end 803 of the heart valve prosthesis reduces, reduces the proximal end of the heart valve prosthesis
803 obstructions being subject to when passing through primary aortic valvular ring, the proximal end 803 for being conducive to the heart valve prosthesis successfully move
Side to aortic valvular ring far from left ventricle reduces conveying difficulty.
After the heart valve prosthesis 800 reaches accurate location, filled media, proximal loop are filled with into fillable structure 813
Chamber 807a and distal end ring cavity 807b reaches expanded state, and proximal end ring cavity 807a expands outwardly the application of proximal annular rim pipeline 8011
Active force, overcomes trend of the proximal annular rim pipeline 8011 to contract, and circlecuf 802 is matched with the formation of aortic valve 34
It closes, the heart valve prosthesis 800 realization is fully deployed.
After being filled with filled media in the ring cavity 807a of proximal end, proximal annular rim pipeline 8011 is filled Jie to the trend of contract
The support force that matter generates is overcome, and the proximal end 803 of the heart valve prosthesis by compression swelling, guarantees heart valve prosthesis 800 at once
It is fully deployed.The pressure adjustable that filled media is injected into fillable structure 813 can determine injection filled media according to demand
Pressure.
The proximal end 803 of heart valve prosthesis can reduce cross section when being not affected by the support force of fillable structure 813 automatically
Profile enters aorta efferent tract convenient for the proximal end 803 of heart valve prosthesis, reduces the friction to aortic valvular ring, reduction is cut to pieces
A possibility that rubbing calcified tissue quick can cross valve and a possibility that cerebrovascular stroke, there is very high clinic to answer
With value.
Also, heart valve prosthesis 800 provided by the invention has preferably recyclable, relocatable performance, anti-valve week
It is good to leak effect, is readily delivered and discharges, can be accurately positioned, convenient for operation, is conveniently adjusted to the direction with heart and keeps coaxial
Property, compressibility is high, can effectively reduce blood vessel and disease occurs, and reduces blocking coronary artery and causes the general of electrocardio block
Rate, and without using anti-coagulants throughout one's life, it is more suitable for aortostenosis patient, keeps clinical manipulation more convenient.
Referring to figure 2. with Fig. 8 A, when which navigates to aortic valvular ring, proximal annular rim pipeline 8011
It is located at the side of the close aorta 36 of aortic valvular ring, distal annular rim pipeline 8012 and distal end ring cavity with proximal end ring cavity 807a
807b is located at the side of the close left ventricle 32 of aortic valvular ring;Made with one end that heart valve prosthesis 800 is located at aorta 36
For the proximal end 803 of heart valve prosthesis, one end of left ventricle 32 is located at as heart valve prosthesis using heart valve prosthesis 800
Distally 804.Heart valve prosthesis 800 further includes waist 805, and waist 805 has and can be considered as tubular element or double-curved shapes
Shape, waist 805 arranges aortic valve 34.
Referring to figure 2., Fig. 8 A and Fig. 8 B, in nearside, the proximal end 803 of heart valve prosthesis forms hoop or ring to seal blood flow
To prevent it from reentering left ventricle 32;The distal end 804 of heart valve prosthesis can also form hoop or ring with seal blood from
And its flow forward is prevented to pass through flow pass.
Valve 104 is fastened on circlecuf 802, and circlecuf 802 is played a supporting role, and valve 104 is in circlecuf
Tissue ingrowth can occur in 802.In the case where taking out flat state, circlecuf 802 cannot provide support.
The direction that distal annular rim pipeline 8012 is directed toward proximal annular rim pipeline 8011 is denoted as first direction, by proximal annular rim pipe
The direction of the distally directed circulating line 8012 in road 8011 is denoted as second direction.Valve 104 is placed in circlecuf 802, wherein
Valve 104 is configured as allowing flowing of the fluid of blood in one direction.Valve 104 can be configured as in response to by heart
The movement of the haemodynamics of pump blood moves between " opening " configuration and " closing " configuration: in " opening " configuration, blood
Liquid rushes at heart valve prosthesis 800 in a first direction, is discharged in aorta 36 from left ventricle 32;It is configured in " closing "
In, blood is prevented from flowing back through valve 104 in a second direction.In some embodiments, valve 104 is tissue valve prosthesis.Into
One step, the thickness of tissue valve prosthesis is equal to or more than 0.011 inch;Preferably, the thickness of tissue valve prosthesis is equal to or more than 0.018
Inch.Valve 104 can have the overall diameter of the expansion more than or equal to 22mm and the tissue greater than or equal to about 0.011 inch
Thickness.The compression diameter of heart valve prosthesis 800 can be less than or equal to about 6mm or 18Fr.
As shown in Fig. 7 A- Fig. 7 B, valve 104 is preferably tectotype heart valve comprising the group of dimensionally stable, pre-align
Knit leaflet.Specifically, valve 104 may include multiple tissue leaflets, tip templating and attached of these tissue leaflets at them
It is connected together, to form the tissue leaflets component of the consistent engagement of dimensionally stable.In feasible single technique, each tissue is small
Leaf is not connected mutually, single tissue leaflets can be independently sewn on circlecuf 802, and each tissue leaflets is opposite
Together.Therefore, suture can comparably bear load force.Each tissue leaflets includes fixed to consolidating on circlecuf 802
Deckle edge 1041 and free edge 1042.The opening of free edge 1042 then allows blood to flow along first direction, free edge
1042 closings then prevent blood from flowing in a second direction.In some embodiments, tissue leaflets are by being only attached to annular sleeve
Band 802 connects to realize.
Connection between valve 104 and circlecuf 802 includes that sewing, socket, bonding, intervention, welding or interference are matched
Close etc..Valve 104 can be attached before the transplant before encapsulation or in hospital;Most of valve 104 can be
It suspends in the fixed solution of glutaraldehyde.
In some embodiments, valve 104 can be constructed with flexible tissue leaflet or polymer leaflet.For example, valve
Film 104 can be obtained from the heart valve of pig;Or it is constructed by other biological material, the pericardium of such as ox or horse.Valve 104
In biomaterial usually have the profile and surface characteristics of laminar-flow type or non-turbulent flow blood stream be provided, it is possible to reduce blood vessel occurs
Interior agglomeration.Natural tissues valve can be obtained from animal species, typically mammality, such as the mankind, bovid, pig canine,
Sea dog or kangaroo;These tissues can be from heart valve, aortic root, aorta wall, aorta leaf, pericardial tissue such as pericardium
It is obtained in piece, bypass graft, blood vessel, Human Umbilical Cord's tissue etc..These natural tissues are usually soft tissue, and are generally included
Material containing silica gel.These tissues can be living tissue, de- cell tissue or reconstruct cell tissue.Tissue can pass through friendship
Connection or non-crosslinked forms are fixed, to provide mechanical stability.It is typically fixed, but can also made using glutaraldehyde or formaldehyde
With other fixatives, such as other dialdehydes, epoxide, Geniposide and its growth.Depending on the type of tissue, purposes with
And other factors.
Valve 104 installation is located at proximal end 803 and the heart valve prosthesis of heart valve prosthesis to circlecuf 802
Distally between 804, so that heart valve prosthesis 800 arranges aortic valve 34 or extends across actively under expanded state
Position before arteries and veins valve 34, and replace the function of aortic valve 34.Distally 804 it can have size and shape appropriate,
So that it is not interfered mitral peculiar function, but still suitably fastens valve.For example, in the distal end of heart valve prosthesis
804 can jagged, recess or notch to prevent interference mitral valve.Proximal end 803 can be designed to be located in aortic root;It is excellent
Selection of land, proximal end 803 can shape in this way, i.e., it maintains the good juxtaposition with aorta endwall, to prevent to move backward
Move up into left ventricle 32.In some embodiments, by configuring the extended height of heart valve prosthesis 800, to avoid interference
Coronary artery.
The heart valve prosthesis 800 can be stably positioned in aortic valvular ring, and can mitigate to hook, suspension hook with
And the needs to vascular wall interference fit, and can be pacified in the case where the dilatation balloon for not being used for radial dilatation is assisted
It puts, therefore reduces the Obstruction duration of aortic valve 34 and blood vessel, provide more comforts for patient and provided for doctor
More times carry out suitably exact placement device.Heart valve prosthesis 800 can be moved or be taken out, and can execute multiple movement
Or take out until heart valve prosthesis 800 is for good and all separated with transportation system, permission tests the heart before separating with transportation system
Whether whether dirty valve prosthesis 800 have correct function, leakproofness and size suitable.
With reference to Fig. 9, it includes proximal end ring cavity 807a, distal end ring cavity 807b and column sections 806 that structure 813, which can be filled,;Proximal loop
Chamber 807a, distal end ring cavity 807b and column sections 806 limit filling channel 808, i.e. proximal end ring cavity 807a, distal end ring cavity 807b respectively
One or more filling channels 808 can be formed together with column sections 806;Filling channel 808 can be by air, liquid or can
Filled media is filled.Filling channel 808 can receive filled media to fill with typically fillable structure 813.Expanded state
Under, proximal end ring cavity 807a, distal end ring cavity 807b and column sections 806 can for heart valve prosthesis 800 provide structural support and/or
Heart valve prosthesis 800 is fastened in heart by help.Take out flat state (i.e. the state of fill-media-free in filling channel 808)
Under, heart valve prosthesis 800 is usually the thin amorphous component of flexibility, and small outline form can advantageously be presented.
The section of filling channel 808 can be round, ellipse, square, rectangle or parabola shaped.Circular cross-section can
Diametrically to change to about 0.100 inch from about 0.020 inch, wall range can change to about from 0.0005 inch
0.010 inch.Depending on required cuff thickness and required intensity, elliptic cross-section can have 2 or 3 to 1
Aspect ratio.
Column sections 806 are between proximal end ring cavity 807a and distal end ring cavity 807b, proximal end ring cavity 807a and distal end ring cavity 807b
The plane at place is without column sections 806, therefore column sections 806 not will increase the radial thickness and distal loop of proximal loop chamber 807a when folding
The radial thickness of chamber 807b, please refers to Fig. 8 A- Fig. 8 B and Fig. 9, is unfolded column sections 806, column sections 806 not with proximal end ring cavity 807a
Radially superposed with distal end ring cavity 807b, column sections 806 do not increase the radial thickness of fillable structure, because in proximal end ring cavity
Do not have radially superposed between 807a and distal end ring cavity 807b, is limited so that channel is located at by proximal end ring cavity 807a and distal end ring cavity 807b
In fixed radial thickness surrounds.In another embodiment, column sections 806 can be wider than proximal end ring cavity in radial directions
807a and distal end ring cavity 807b, so that proximal end ring cavity 807a and distal end ring cavity 807b, which is located at from column sections 806, limits ground diameter to thickness
In degree surrounds.
Further, each of proximal end ring cavity 807a and distal end ring cavity 807b may have about 0.090 inch
Diameter of section.Preferably, proximal end ring cavity 807a and distal end ring cavity 807b can have about 0.060 inch of diameter of section.
Since filling channel 808 is usually surrounded by circlecuf 802, the attachment or encapsulation of these filling channels 808
It can be in close contact with circlecuf 802.Fillable structure 813 can be sewn on circlecuf 802, alternatively, package is to by ring
It is intracavitary and go around onto circlecuf 802 made of shape cuff 802.Can in any different mode by proximal loop chamber 807a and
Distal end ring cavity 807b is fastened to circlecuf 802, for example, proximal end ring cavity 807a and distal end ring cavity 807b are encapsulated by cuff material
Material is made and is stitched to the intracavitary of circlecuf 802.
Specifically, structure 813 can be filled and be equipped with folding part in the proximal end of heart valve prosthesis 803 with reference to Fig. 8 B and Fig. 8 C
801, proximal annular rim pipeline 8011 is formed, proximal end ring cavity 807a is fastened in proximal annular rim pipeline 8011;In heart valve prosthesis
Distal end 804, structure 813 can be filled and be equipped with folding part 801, form distal annular rim pipeline 8012, distal end ring cavity 807b is fastened on
It is formed in distal annular rim pipeline 8012.Folding part 801 can be fastened by suture needle line or suture 812.In expanded state, heart
Valve prosthesis 800 can be by supporting around 806 part of column sections of circlecuf 802.
Circlecuf 802 includes the cuff waist 8023 between the folding part 801 at both ends, cuff waist 8023 and can
Column sections 806 in interstitital texture 813 collectively form the waist 805 of heart valve prosthesis 800;The proximal end of heart valve prosthesis
803 include proximal end ring cavity 807a and proximal annular rim pipeline 8011;The distal end 804 of heart valve prosthesis include distal end ring cavity 807b and
Distal annular rim pipeline 8012.In some embodiments, as shown in figure 9, column sections 806 include multiple axis along circlecuf
The column tube body that direction 881 extends, each column tube body limit one section of filling channel 808 respectively.Further, column sections 806
It is wrapped up by circlecuf 802;Specifically, cuff waist 8023 forms multiple axis directions along circlecuf 802 by suture
The channel of extension accommodates each column tube body in column sections 806 respectively.Preferably, the axis of the column tube body and circlecuf
Line 880 is parallel.
With reference to Fig. 8 B and Fig. 9, a part of cross-sectional direction that can be parallel to proximal end ring cavity 807a of column sections 806 is prolonged
It stretches, and can be packaged in the folding part 801 of heart valve prosthesis 800.When heart valve prosthesis is by compression or folding, this
Kind arrangement can also contribute to reduce cross section profile.
In order to keep the heart valve prosthesis 800 around valve annulus in place, heart valve prosthesis 800 can have more
Kind global shape, for example, hourglass shape.Fillable structure 813 is designed for any combination of three kinds of functions: (1) for by the heart
The tissue that dirty valve prosthesis 800 arranges provides support;(2) intensity axially and radially and just is provided for heart valve prosthesis 800
Degree;(3) support is provided for valve 104.
Circlecuf 802 of various shapes can be manufactured to conform better to interpersonal anatomical structure difference.Such as
It is upper described, these shapes may include simple cylindrical body, hyperboloid, middle section have larger diameter and one or both ends have it is smaller
The device of diameter, it is funneling configuration or other meet the shape of native anatomical structure.The shape of heart valve prosthesis 800 is preferred
With contoured to engage native anatomical structure feature, so that anti-locking apparatus is on nearside and distal direction in this way
Migration.In one embodiment, means for engaging is characterized in aortic root or aortic valve 34.In another embodiment party
In formula, means for engaging is characterized in a part of native valve annulus, native valve or native valve.In certain embodiments
In, the engagement of heart valve prosthesis 800 is to prevent the feature of migration to have the diameter difference between 1% and 10%;Preferably, heart valve
The engagement of film prosthese 800 is to prevent the diameter difference of the feature migrated between 5% and 40%.In some embodiments, diameter
Difference is limited by the free shape of heart valve prosthesis 800.In another embodiment, diameter difference only prevents in one direction
Migration.In another embodiment, diameter difference prevents from migrating in two directions, for example, nearside and distal side or fall back and
Advance.Similar to surgical valve, the diameter of heart valve prosthesis 800 will be from about 14mm to becoming in the diameter range of about 30mm
Change, and has in the place that the leaflet of the valve of heart valve prosthesis 800 104 is placed from about 10mm to the height of about 30mm
Range.The part that heart valve prosthesis 800 is used to replace in aortic root can have larger diameter, and preferred scope is from about
20mm to about 45mm.In some embodiments, when being filled up completely, heart valve prosthesis 800 can have greater than about 22mm
Outer diameter.
In one embodiment, circlecuf 802 will have the diameter between about 15mm and about 30mm, and about 6mm
Length between about 70mm.The thickness of wall will have from about 0.01mm to the ideal range of about 2mm.As described above, annular sleeve
Band 802 can obtain longitudinal bracing from fillable structure 813 in the original location to provide axial separation.Circlecuf 802 it is interior straight
Diameter can have fixed dimension, beat on and off to provide constant size for the attachment of valve 104 and provide predictable valve
Close function.The part of the outer surface of circlecuf 802 can be optionally complying with and allow heart valve prosthesis 800 reach with
The interference fit of native anatomical structure.
When heart valve prosthesis 800 is filled, circlecuf 802 and fillable structure 813, the anatomical structure phase with patient
Adaptation, to provide better seal between the anatomical structure of patient and heart valve prosthesis 800.
The heart valve prosthesis 800 of different-diameter may be needed to replace various sizes of native valve.Dissection is tied
Different location in structure will also need the heart valve prosthesis 800 or anchoring device of different length.For example, because tubulose is dynamic
The position in arteries and veins hole (left and right coronary artery) is designed to the length that the valve of replacement native aortic valve film needs to have relatively short
Degree.Because the anatomical structure of pulmonary artery allows extra length, the valve for being designed to replace or supplement cusps of pulmonary valve can have
There is sizable length.
Circlecuf 802 may include thin flexible tubular substance, is suitble to during conveying, providing compression shape
It conveys inside sheath.These materials are bio-compatibles, and can help to the commissural growth that group is woven in autologous tissue.Usually
In the case of, circlecuf 802 can be made from many different materials, such as terylene, TFE, PTFE, ePTFE, metal knitted
Object, braided material or other common medical materials, such as dacron fabric;Line of knitting in production circlecuf 802 can be with
Using such as stainless steel, platinum, MP35N, polyester fiber or other portable metals or polymer.These materials can also make
With hot (direct or indirect) sintering technology, laser energy sources, ultrasonic technique, molding or hot forming technology come casting mold, extruding
Or it is stitched together.
Circlecuf 802 can be manufactured by various methods.In one embodiment, circlecuf 802 is by fabric system
At typically used as in vasotransplantation or the fabric of the cuff of surgical implantation prosthetic heart valve similar to those.For annular
Fabric is preferably knitted as tubular form by some parts of cuff 802.It can also be sheet material by weaving textile.In a reality
It applies in mode, is preferably doubled yarn for manufacturing the yarn of fabric, but monofilament or braiding yarn also can be used.Yarn is straight
The useful range of diameter is from the diameter close to 0.0005 inch to the diameter close to 0.005 inch.Depending on having made of fabric
It is mostly tight.Preferably, with the yarn between per inch about 50 and about 500 come braided fabric.In one embodiment, with every
The diameter of inch 2 00 yarn number or number of latitude and 18mm carry out braided fabric pipe.Every one thread is made of the silk of 20 PET materials.For
The single wall of pipe, the final thickness of this braided fabric pipe are 0.005 inch.It is taken turns depending on required heart valve prosthesis 800
Different weaves can be used to the required permeability to blood or other fluids in wide and fabric.Any life can be used
Yarn is made in object biocompatible material, and some embodiments include nylon and PET.The combination of other materials or other materials
Possible, including polytetrafluoroethylene (PTFE), fluoropolymer, polyimides, metal, the metal include such as stainless steel, titanium alloy,
Nitinol or other shapes memorial alloy, the combined alloy mainly comprising cobalt, chromium, nickel and molybdenum.Fiber can also be added
Into yarn to increase intensity or radiopacity, or to convey medicament.Fabric pipe can also be manufactured by weaving.
It is false can be bonded or are combined together to form required heart valve for fabric sewing, suture, sealing, dissolution
The shape of body 800.Preferred method for the part of fabric to be attached together is sewing.Preferred embodiment uses poly- third
Alkene monofilament suture material, diameter is close to 0.005 inch.The diameter range of suture material can be from about 0.001 inch to about
0.010 inch.In higher stress position, such as in the valve commissure for being attached to cuff, larger suture material also can be used.
Suture material can be the material of any acceptable heart valve prosthesis grade.It is simultaneous that such as polyacrylic biology is preferably used
Capacitive suture material.Nylon and polyethylene are also usually used suture material.The combination of other materials or other materials
It is possible, including polytetrafluoroethylene (PTFE), fluoropolymer, polyimides or metal, which includes that such as stainless steel, titanium close
Gold, Kevlar, Nitinol, other shapes memorial alloy, the alloy mainly comprising cobalt, chromium, nickel or molybdenum.Preferred suture is single
Silk design.Also multiply braiding or plying suture material can be used.Preferred bind is using certain form of lock stitch
It threads, there is following design, i.e., if when suture is broken over a part of its length, the entire development length of suture will
Resistance is broken.And suture still will generally execute the function that tissue layer keeps together.
The thickness range of the fabric of circlecuf 802 can be from about 0.002 inch to 0.020 inch.Count can also
To be adjusted to allow the comparison of tissue growth and encirclement fabric completely loose through the very tight braiding of fabric from anti-Hemostatic Oral Liquid
Braiding.In some embodiments, fabric can have about 20 daniers or lower linear mass density.
In some embodiments, heart valve prosthesis 800 has the diameter of the expansion more than or equal to 22 millimeters, and
Maximum compression diameter less than or equal to 6 millimeters (18F).
Filling channel 808 can have three connectivity ports 809 to be connected to delivery conduit 900 by PFL pipeline 916.
In some embodiments, at least two in connectivity port 809 also serve as fill port, and filled media, air or liquid
Body can be introduced in filling channel 808 by the fill port.
By suitable bindiny mechanism, PFL pipeline 916 can be connected to connectivity port 809.Referring to FIG. 10, PFL is managed
Connection between road 916 and connectivity port 809 is to be threadedly coupled.In some embodiments, filling-valve 810 is present in connecting pin
In mouth 809, and filled media can be prevented to overflow filling channel 808 after PFL pipeline is separated.In some embodiments
In, distal end ring cavity 807b and proximal end ring cavity 807a filling can independently be.It in some embodiments, can be respectively from pillar
Portion 806 and proximal end ring cavity 807a fill for distal end ring cavity 807b.During heart valve prosthesis 800 is placed on implantation position,
Be separately filled can be it is useful.
Fig. 9 is please referred to, distal end ring cavity 807b and column sections 806 can combine, so that the filling channel of distal end ring cavity 807b
808 are in fluid communication with a part of filling channels 808 of column sections 806.The filling channel 808 of proximal end ring cavity 807a can also be with branch
A part of filling channel 808 in column portion 806 is connected to.In this way, a part of proximal end ring cavity 807a and column sections 806
Filling channel 808 can be independently filled with relative to another part filling channel 808 of distal end ring cavity 807b and column sections 806.
In other embodiments, the filling channel 808 of proximal end ring cavity 807a can be with the filling channel of column sections 806
808 connections, and the filling channel 808 of distal end ring cavity 807b is not connected to the filling channel of column sections 806;Two groups can be filled out
It fills channel 808 and is connected to independent PFL pipeline 916 to promote independent filling.
In other embodiments, the filling of all proximal end ring cavity 807a, column sections 806 and distal end ring cavity 807b are logical
Road 808 can be in fluid communication with each other, they are filled from the same filling device.
In another embodiment, the filling of all proximal end ring cavity 807a, column sections 806 and distal end ring cavity 807b are logical
Road can be separated, and therefore utilize three filling devices.
Filling channel 808 is filled for convenience, valve system is equipped in filling channel 808, which allows liquid
Body unidirectionally passes through.Please refer to Fig. 9, it is adjacent with connectivity port 809 to may reside within filling channel 808 for two filling-valves 810
End.These filling-valves 810 are used to fill and exchange the fluid of such as salt water, contrast medium (developer) and filled media.Depend on
It can be different in the length of the size and geometry complexity of heart valve prosthesis 800, filling channel 808.
With reference to Fig. 9, in example embodiment, filling-valve 810 can be realized to be detachably connected with PFL pipeline 916, so as to
It is separated in PFL pipeline 916 and heart valve prosthesis 800.In order to make reliably to fasten between filling-valve 810 and PFL pipeline 916,
This connection can be screw or threaded connection, collet system or interference fit.Between the end of filling channel 808,
Other check valves 811 may be present to allow fluid one direction to flow through, to allow filling and the fluid at every end of filling channel 808
Exchange in one direction.When with salt water and contrast medium filling, once heart valve prosthesis 800 is placed in the position of requirement
It sets, so that it may which salt water and comparison agent solution are substituted by curable or hardening filled media.Because can be from delivery conduit 900
Proximal end introduce filled media, so the fluid containing salt water and contrast medium can be pushed out from the other end of filling channel 808.
Once filled media is completely instead of initial fluid, PFL pipeline 916 can then be separated with from heart valve prosthesis 800, simultaneously
Heart valve prosthesis 800 keeps filling and pressurization.By being located at the filling-valve 810 of filling channel 808, pressure may remain in the heart
In dirty valve prosthesis 800.
As shown in Figure 10, in example embodiment, filling-valve 810 can have ball 303 and soft seal 304 even
Allow fluid process and the sealing when disconnecting when connecing.In some cases, heart valve prosthesis 800 is with three or more connections
Port 809, but only there are two have to be attached with filling-valve 810.There is no the connectivity port 809 of filling-valve 810 that phase can be used
With attachment device, such as screw or screwing element, because connectivity port 809 thus be not used in be connected to fillable structure 813 and
The filling of fillable structure 813, therefore filling-valve 810 is not necessary.In other embodiments, all three connectivity ports
809 may have filling-valve 810 to introduce fluid or filled media.
With reference to Figure 10, filling-valve 810 may include the tubular portion 312 with soft seal 304 and ball 303, with creation
Sealing mechanism 313.In one embodiment, the length of tubular portion 312 is about 0.5cm to about 2cm, and overall diameter is about
0.010 inch to about 0.090 inch, wall thickness is about 0.005 inch to about 0.040 inch.Material may include many polymerizations
Object, such as nylon, polyethylene, polyetheramides, polypropylene or other such as the ordinary matter of stainless steel, Nitinol or
Other are used for the metallics of medical device.Soft seal material can be introduced as liquid silastic or can produce it is cured its
His material, therefore allow to carry out the heart or punching across sealing material and construct through-hole to form center cavity.Soft seal 304 can
To be adhered to the internal diameter of the wall of the tubular portion 312 with the through-hole flowed for fluid.Ball 303 can be in tubular portion 312
It is moved in internal diameter, in internal diameter, ball 303 is located in filling channel 808 under an end sealed pressure, and with PFL pipeline
916 introducing and be moved to other directions, but do not allow to migrate it is too far because stop bulb stopper 305 prevents ball 303 from being moved to and fill out
It fills in channel 808.Since PFL pipeline 916 is to be screwed into connectivity port 809 by screw, therefore ball 303 moves into opening position
It sets to allow the fluid communication between filling channel 808 and PFL pipeline 916.When apart, ball 303 can be towards soft seal
304 move and stop the fluid communication outside any filling channel 808 and heart valve prosthesis 800 is made to pressurize, reality in addition
The mode of applying can use spring mechanism for ball 303 back to sealing station, and the sealing device that other shapes can be used comes
Replace ball 303.Also duck-beak type sealing mechanism or disk valve can be used to prevent fluid from leaking, and be heart valve prosthesis
800 provide closing system.
Preferably, as shown in figure 11, before assembling with circlecuf 802, fillable structure 813 can expand into tubulose,
Fillable structure 813 includes two filling-valves 810, is respectively located at one end of fillable structure 813 and close to proximal end ring cavity
The first filling-valve 8101 of 807a and the other end positioned at fillable structure 813 and the second filling close to distal end ring cavity 807b
Valve 8102;Fillable structure 813 further includes the check valve 811 between proximal end ring cavity 807a and distal end ring cavity 807b.Herein
In embodiment, two filling-valves 810 can serve as filled media enter channel, two filling-valves 810 respectively with PFL pipeline
916 are connected through a screw thread.For example, filled media enters in fillable structure 813 by the first filling-valve 8101, along tubulose
Fillable structure 813, first fill proximal end ring cavity 807a refill distal end ring cavity 807b after check valve 811.Extra
Filled media can be entered in another PFL pipeline 916 being connected with the second filling-valve 8102 by the second filling-valve 8102.
In implantation, heart valve prosthesis 800 is in the state of compression, and all filled medias in structure 813 can be filled
It is discharged, such as the part of 811 or more check valve, i.e., can be filled out by first including all filled medias in proximal end ring cavity 807a
Valve 8101 is filled to be vacuumized and be sucked out by the syringe that the female Luer 917 with the end of PFL pipeline 916 is connected;Check valve 811 with
Under part, that is, include distal end ring cavity 807b in all filled medias can by the second filling-valve 8102 by with PFL pipeline
The connected syringe of the female Luer 917 of 916 end is vacuumized and is sucked out.
As shown in Fig. 4 A- Fig. 4 C, the proximal end ring cavity 807a and distal end ring cavity of the heart valve prosthesis 800 in compressive state
807b overlaps, and expansion in situ, the heart valve prosthesis of folding cannot be introduced into a left side along seal wire at the annulus of human body
After ventricle, filled media is injected into heart valve prosthesis 800 by the PFL pipeline 916 being connected with filling-valve 810, usually
Saline solution containing developer, the Each part of heart valve prosthesis 800 are successively quickly unfolded in left ventricle 32, and inspection is passed through
After survey, by filling-valve 810 that proximal loop chamber 807a pumping is flat, the proximal end ring cavity 807a taken out under flat state is in unformed shape
State, cross-sectional profiles can reduce, and due to the presence of check valve 811, distal end ring cavity 807b is still within full state.
Then heart valve prosthesis 800 is pulled back by delivery conduit 900, namely is pulled towards aorta, proximal end ring cavity
807a is entered in aorta by aortic valvular ring, and distal end ring cavity 807b is remained in left ventricle.At this point, again by filling out
It fills valve 810 to continue to inject filled media into heart valve prosthesis 800, proximal end ring cavity 807a is again at expanded state, can be with
Play supporting role.
It as shown in figures 5 a-5e, can will not be curable if the releasing position of heart valve prosthesis 800 does not meet demand
Filled media extraction, adjust reinject after good position can not cured filled media, carry out functional test and assessment again, directly
To meeting demand.
If the off size suitable or multiple adjustment of heart valve prosthesis 800 does not meet demand still, can be by heart valve
In film prosthese 800 can not the extraction of cured filled media, heart valve prosthesis 800 becomes unformed thin state, can
To execute the operation of recycling, i.e., withdrawn from except human body in the catheter sheath by heart valve prosthesis 800 by establishing blood vessel approach.
If the size of heart valve prosthesis 800 and releasing position all meet demand, curable filled media can be used
Can not cured filled media cement out.Displaced operation are as follows: curable filling is injected by the first filling-valve 8101
Medium, cured fillable medium by filling channel 808 can not cured filled media from the second filling-valve of valve 8102
It squeezes out, the exchange of filled media can be completed.It can be heart after curable filled media solidifies in filling channel 808
Valve prosthesis 800 provides more stable support.And the pressure adjustable of filled media is injected into filling channel 808, it can basis
Demand provides suitable pressure, such as 5atm, 10atm, 16atm or 20atm.
In one embodiment, salt water and contrast medium are filled with filling channel 808 with impermeable under fluoroscopy first
Ray shows.This can be such that positioning of the heart valve prosthesis 800 at implantation position is more easier.In filling out for such as pressure charging pump
Fill set or the assistance of other devices under, can by this fluid from the proximal end of delivery conduit 900 introduce, thus with controlled manner
It pressurizes to fluid.This fluid can be shifted from the proximal end of delivery conduit 900 by PFL pipeline 916, wherein PFL pipeline 916
Heart valve prosthesis 800 is connected to by the connectivity port 809 of the end of each filling channel 808.
In some embodiments, the part of circlecuf 802 can be radiopaque to assist to show heart valve
The position and direction of prosthese 800.The marker made of platinum or tantalum or other suitable materials can be used.These markers can
To be used to identify the key area that must be properly placed of valve, for example, needing to close valve 104 for aortic valve
It suitably is placed at seam relative to coronary artery.
In order to make nearly heart valve prosthesis proximal end 803 outer profile perimeter, from expanded state to take out flat state can
Biggish reduction amplitude is generated, inventor has done further improvement design to the heart valve prosthesis.
Embodiment one
The material for making proximal annular rim pipeline 8011 includes elastic material, so that proximal annular rim pipeline 8011 has self-constriction
Property.
When proximal end ring cavity 807a is under expanded state, the filled media in the ring cavity 807a of proximal end generates proximal end ring cavity 807a
Outside expansionary force, the expansionary force are transmitted on proximal annular rim pipeline 8011, can overcome proximal annular rim pipeline 8011 itself
Elastic force.The outer profile that the heart valve prosthesis 800 can form proximal annular rim pipeline 8011 as shown in Figure 7 A is approached and is omited
Greater than the outer profile of distal annular rim pipeline 8012, the outer profile etc. of proximal annular rim pipeline 8011 as shown in Figure 8 A can also be formed
In the outer profile of distal annular rim pipeline 8012.
If proximal annular rim pipeline 8011 and proximal end ring cavity 807a are all made of the weaker flexible material of elastic property, do not have
Self-constriction, then when proximal end ring cavity 807a, which is in, to be taken out under flat state, as shown in Figure 6 A and 6 B, the heart valve prosthesis 800
Proximal end since diminution more by a small margin can be generated by the outer profile of the effect pulled, the proximal end 803 of heart valve prosthesis.
In heart valve prosthesis 800 provided in this embodiment, when proximal end ring cavity 807a, which is in, to be taken out under flat state, proximal loop
Shape pipeline 8011 is shunk under natural resiliency effect, so that the outer profile of the proximal end 803 of the heart valve prosthesis generates larger amplitude
The diminution of degree, as illustrated in figs. 12 a and 12b, allow the proximal end 803 of the heart valve prosthesis traction action more easily
Pass through aortic valvular ring.
In some embodiments, the elasticity modulus of the material of proximal annular rim pipeline 8011 is less than distal annular rim pipeline
The elasticity modulus of 8012 material, so that during from fillable 813 expanded state of structure to the flat state of pumping, proximal annular rim pipe
The amplitude that road 8011 reduces is greater than the amplitude of distal annular rim pipeline 8012.The fill-media-free in the ring cavity 807a of proximal end, in pumping
When under flat state, the perimeter of the outer profile of proximal annular rim pipeline 8011 is less than the perimeter of the outer profile of distal annular rim pipeline 8012,
The shape of the heart valve prosthesis 800 is substantially tapered, and the proximal end 803 of the heart valve prosthesis is facilitated to pass through aortic valvular ring.
When circlecuf 802 is made of fabric, which includes the more of the circumferential direction extension around circlecuf 802
More warps 8022 of root weft 8021 and the extension of axis direction 881 along circlecuf.Make proximal annular rim pipeline 8011
At least one is that elasticity knits line in more wefts 8021, so that proximal annular rim pipeline 8011 has stronger elasticity, can taken out
Self-constriction is carried out under flat state.
Specifically, the weft for making proximal annular rim pipeline 8011 can be that elasticity knits line, can also only some be
Elasticity knits line.Preferably, when only some weft 8021 is that elasticity knits line, elasticity is knitted line and is replaced point with non-resilient line of knitting
Cloth.Whole wefts 8021 of production proximal annular rim pipeline 8011 are that elasticity knits line, proximal annular rim pipeline 8011 can be made to have more preferable
Self-Shrinkage Property, bigger convergent force is provided, can by the outer profile of the proximal end 803 of the heart valve prosthesis shrink it is smaller.
In comparison, a part of weft 8021 is that elasticity knits line, and the distribution mode of line is knitted by design flexibility, makes proximal annular rim pipeline
In the case that 8011 have preferable Self-Shrinkage Property, the difficulty of the fabric of production circlecuf 802 can be reduced, can also be dropped
The low difficulty by fillable structure 813 together with the loading of proximal annular rim pipeline 8011, is easier to the heart valve prosthesis 800
Production.
In order to make proximal annular rim pipeline 8011 that there is stronger Self-Shrinkage Property, more of proximal annular rim pipeline 8011 are made
At least one is that elasticity knits line in warp 8022.The warp 8022 for making proximal annular rim pipeline can be that elasticity knits line, can also
Using only some as elasticity knit line.Whole warps 8022 of production proximal annular rim pipeline 8011 are that elasticity knits line, can be by the heart
The outer profile diameter of the proximal end 803 of dirty valve prosthesis is shunk smaller.A part of warp 8022 is that elasticity knits line, more conducively may be used
Interstitital texture 813 is placed in the production operation in proximal annular rim pipeline 8011.
Under normal conditions, weft 8021 is arranged around the circumferential direction of circlecuf 80.As shown in FIG. 13A, Figure 13 A is that will knit
Floor map of the object after the expansion of axis 880 of circlecuf, the axis of plane and circlecuf that weft 8021 is surrounded
880 is substantially perpendicular, i.e. the plane surrounded of weft 8021 is parallel with the cross section of circlecuf 802.In order to improve the heart
The shrinkage of dirty valve prosthesis 800, inventor make an adjustment the set-up mode of fabric.
As schemed in one embodiment of the present invention, as shown in Figure 13 B, the plane and circlecuf that weft 8021 is surrounded
Cross-sectional direction 882 between angle be denoted as α, 15 °≤α≤75 °, to improve the shrinkage of proximal annular rim pipeline 8011,
So that can not only reduce the whole cross section outer profile of proximal annular rim pipeline 8011 in the case where taking out flat state, but also can reduce close
Hold the pipe diameter of circulating line 8011.
Further, 30 °≤α≤60 °.It is highly preferred that α=45 °, make the whole cross section of proximal annular rim pipeline 8011
Outer profile and pipe diameter more balancedly reduce.
Under normal conditions, the extending direction of warp 8022 and the extending direction of weft 8021 are perpendicular.As another real
Mode is applied, the fabric for making the material of proximal annular rim pipeline 8011 includes more wefts 8021 and Duo Gen warp 8022, weft
8021 around circlecuf 802 circumferential direction extend, between the extending direction of warp 8022 and the extending direction of weft 8021
Angle is less than 90 °;And the plane that weft 8021 is surrounded is parallel to the cross-sectional direction 882 of circlecuf;8022 edge of warp
What the axial screw of circlecuf 802 extended, at least one is that elasticity knits line, the elastic force of warp 8022 in more warps 8022
With circumferential component, weft 8021 can be driven to move together, reduce the proximal end 803 of the heart valve prosthesis.Preferably,
More circumferentially distributed around the axis 880 of circlecuf for the elastic warp 8022 for knitting line.
The warp 8022 of fabric knits line using elasticity, and weft 8021 knits line or the use of weft 8021 using non-resilient
Elasticity knits line, and warp 8022 knits line using non-resilient, can reduce the production difficulty of fabric.
The fabric of production circlecuf 802 can form proximal annular rim pipeline 8011, by turning down outward by adjusting bullet
Property knits the position of line on fabric, and the corresponding position of proximal annular rim pipeline 8011 can be made to be equipped with elasticity and knit line.
In one embodiment of the present invention, proximal annular rim pipeline 8011 is close to the side of the axis 880 of circlecuf
It include elastic weft in weft 8021, so that proximal annular rim pipeline 8011 is equipped with bullet close to the side of the axis 880 of circlecuf
Property knits line.Proximal annular rim pipeline 8011 is in contact close to the side of the axis 880 of circlecuf with proximal end ring cavity 807a, is conducive to
Ring cavity 807a in proximal end is driven to shrink, and the profile overall diameter of reduction proximal annular rim pipeline 8011.
In another embodiment of the present invention, the side of axis of the proximal annular rim pipeline 8011 far from circlecuf 802
Weft 8021 in include elastic weft so that the side of axis of the proximal annular rim pipeline 8011 far from circlecuf 802 is equipped with
Elasticity knits line, and the profile interior diameter of proximal annular rim pipeline 8011 is reduced by the inside contraction of proximal annular rim pipeline 8011, from
And drive the diminution of the profile overall diameter of proximal annular rim pipeline 8011.Axis of the proximal annular rim pipeline 8011 far from circlecuf 802
The side of line constitutes the outer profile of the proximal end 803 of the heart valve prosthesis, which shrinks under elastic reaction, is conducive to make
The outer profile of the proximal end 803 of the heart valve prosthesis shrinks smaller, convenient for passing through aortic valvular ring.
In some embodiments, proximal annular rim pipeline 8011, distal annular rim pipeline 8012 and cuff waist 8023 can be with
It makes, is connected together by modes such as sewing, bonding, meltings respectively.
Further, elasticity knits line using degradation material, it is to be implanted in vivo after, elasticity, which knits line, slowly to drop in vivo
Solution reduces the potential adverse effect to human body to reduce the pressure to circlecuf 802 and fillable structure 813.Elasticity is knitted
Line can be made of elastomer, preferably low or animal derived material without immunogenicity;It is adopted it is highly preferred that elasticity knits line
With the material including elastin laminin.
The above-mentioned non-resilient material for knitting line can be terylene, TFE, PTFE or ePTFE.
In one embodiment of the present invention, structure 813 can be filled and use flexible material, and there is preferable plasticity
Can, the fillable stroke of structure 813 under external force is smaller or does not stretch, and under expanded state, the heart valve is false
The shape and size of the proximal end 803 of body are limited by the proximal end ring cavity 807a in structure 813 can be filled.For example, fillable structure
The material that nylon, polyethylene fibre or polyethers acyl etc. are able to maintain that pressure can be used in 813 material.
Embodiment two
As shown in figs. 14 a and 14b, which further includes elastic webbing 400, is connected to proximal annular rim
Pipeline 8011, and along the circumferentially extending of circlecuf 802, make proximal annular rim pipeline 8011 that there is the trend to contract, to subtract
The perimeter of the outer profile of small proximal annular rim pipeline 8011.In the case where proximal end ring cavity 807a is expanded state, elastic webbing 400 is in elongation
State has and shortens, and the trend for driving proximal annular rim pipeline 8011 to shrink together.
When proximal end ring cavity 807a is under expanded state, the filled media in the ring cavity 807a of proximal end generates proximal end ring cavity 807a
Outside expansionary force, the expansionary force are transmitted on proximal annular rim pipeline 8011, can overcome the elastic force of elastic webbing 400.The heart
The outer profile that dirty valve prosthesis 800 can form proximal annular rim pipeline 8011 as shown in Figure 7 A approaches and slightly larger than distal annular rim
The outer profile of the outer profile of pipeline 8012, proximal annular rim pipeline 8011 that can also be as shown in Figure 8 A is equal to distal annular rim pipeline
8012 outer profile.
In heart valve prosthesis 800 provided in this embodiment, when proximal end ring cavity 807a, which is in, to be taken out under flat state, proximal loop
Shape pipeline 8011 is shunk under the elastic reaction of elastic webbing 400, so that the outer profile of the proximal end 803 of the heart valve prosthesis generates
Diminution by a relatively large margin, the perimeter of the outer profile of proximal annular rim pipeline 8011 are less than the week of the outer profile of distal annular rim pipeline 8012
It is long, as illustrated in figs. 12 a and 12b, the proximal end 803 of the heart valve prosthesis is allowed to be easier to pass through actively in traction action
Arteries and veins annulus.
In one embodiment of the present invention, multiple weeks along circlecuf 802 are installed on proximal annular rim pipeline 8011
To the snare 300 of distribution;Elastic webbing 400 is annular in shape, and is arranged in snare 300, and elastic webbing 400 can be stretched in snare 300
Contracting sliding, is on the one hand convenient to elastic webbing 400 and connect with proximal annular rim pipeline 8011, on the other hand make the position of elastic webbing 400
It sets more stable.Preferably, snare 300 is flexible snare.
Further, as shown in figs. 14 a and 14b, axis of the axis of snare 300 perpendicular to circlecuf 802.
Further, proximal annular rim pipeline 8011 is equipped with a plurality of cricoid elastic webbing 400, and each elastic webbing 400 is along ring
Shape cuff 802 it is axial circumferentially distributed, elastic force is applied with each position respectively to proximal annular rim pipeline 8011, is promoted close
Hold circulating line 8011 to contract.Preferably, each elastic webbing 400 is distributed along the axially spaced-apart of circlecuf 802, can be kept away
Exempt to interfere with each other between each elastic webbing 400, so that each position of proximal annular rim pipeline 8011 is more uniformly stressed, makes proximal end
Circulating line 8011 is more uniform steadily to be shunk.
Further, elastic webbing 400 can be set in any position of proximal annular rim pipeline 8011, for example, can both set
In the inner wall of proximal annular rim pipeline 8011, and the outer wall of proximal annular rim pipeline 8011 can be set to;Both proximal annular rim can be set to
The side of the distal end 804 of the separate heart valve prosthesis of pipeline 8011, and the close heart of proximal annular rim pipeline 8011 can be set to
The side of the distal end 804 of dirty valve prosthesis;Both the axis of the separate circlecuf 802 of proximal annular rim pipeline 8011 can be set to
Side, and the side of the axis 880 of the close circlecuf of proximal annular rim pipeline 8011 can be set to.
Preferably, as shown in Figure 14 A- Figure 14 D, elastic webbing 400 is connected to proximal annular rim pipeline 8011 by snare 300
Outer wall.
It is highly preferred that as shown in figs. 14 a and 14b, elastic webbing 400 is located at tucking inside the sleeve far from annular for proximal annular rim pipeline 8011
Side with 802 axis, so that 400 cuff of elastic webbing is in outside proximal annular rim pipeline 8011, convenient for making proximal annular rim pipeline
8011 under the action of elastic webbing 400 to contract.The axis of plane and circlecuf 802 that cricoid elastic webbing 400 is surrounded
Line is perpendicular;Proximal annular rim pipeline 8011 is equipped with the axis along circlecuf 802 as shown in Figure 14B and is equipped with 2 elastic webbings
400, to guarantee good contractive effect.
As another preferred embodiment, as shown in figs.14 c and 14d, proximal annular rim pipeline 8011 is equipped with 4
Elastic webbing 400 is located at top (one of the distal end 804 far from heart valve prosthesis of proximal annular rim pipeline 8011
Side), bottom (close to heart valve prosthesis distal end 804 side), outside (far from circlecuf axis 880 side) and
Inside (close to the side of the axis 880 of circlecuf), 4 elastic webbings 400 act synergistically, can be by the proximal end of heart valve prosthesis
803 shrink smaller, and can be improved shrinks the proximal end 803 of heart valve prosthesis to ensure through the reliable of aortic valvular ring
Property.
In another embodiment of the present invention, elastic webbing 400 is linear, and proximal annular rim pipeline 8011 is equipped with a plurality of edge
The elastic webbing 400 of the circumferentially-spaced distribution of circlecuf 802.Specifically, week of the linear elastic webbing 400 along circlecuf 802
To extension, and both ends are respectively fixed on the outer wall of proximal annular rim pipeline 8011, and the convergent force of multiple elastic webbings 400 is made simultaneously
For proximal annular rim pipeline 8011, proximal annular rim pipeline 8011 can be promoted to contract.
Further, elastic webbing 400 use degradation material, it is to be implanted in vivo after, elastic webbing 400 can in vivo slowly
Degradation reduces the potential adverse effect to human body to reduce the pressure to circlecuf 802 and fillable structure 813.Elasticity
Band 400 can be made of elastomer, preferably low or animal derived material without immunogenicity;It is highly preferred that elastic webbing
400 using the material for including elastin laminin.
In one embodiment of the present invention, structure 813 can be filled and use flexible material, and there is preferable plasticity
Can, the fillable stroke of structure 813 under external force is smaller or does not stretch, and under expanded state, the heart valve is false
The shape and size of the proximal end 803 of body are limited by the proximal end ring cavity 807a in structure 813 can be filled.For example, fillable structure
The material that nylon, polyethylene fibre or polyethers acyl etc. are able to maintain that pressure can be used in 813 material.
Embodiment three
The material of proximal end ring cavity 807a uses elastic material, so that proximal end ring cavity 807a is had the trend to contract, to subtract
The perimeter of the outer profile of small proximal end ring cavity 807a, since proximal annular rim pipeline 8011 wraps up proximal end ring cavity 807a, i.e. proximal annular rim
The inner wall of pipeline 8011 is in contact with proximal end ring cavity 807a, therefore will drive proximal annular rim pipeline when proximal end ring cavity 807a contraction
8011 shrink together, so that the outer profile of the proximal end 803 of the heart valve prosthesis be made to reduce.
When proximal end ring cavity 807a is under expanded state, the filled media in the ring cavity 807a of proximal end generates proximal end ring cavity 807a
Outside expansionary force, the expansionary force can overcome the elastic force of proximal end ring cavity 807a itself.The heart valve prosthesis 800 can be with shape
The outer profile close and slightly larger than distal annular rim pipeline 8012 at the outer profile of proximal annular rim pipeline 8011 as shown in Figure 7 A,
The outer profile that proximal annular rim pipeline 8011 as shown in Figure 8 A can be formed is equal to the outer profile of distal annular rim pipeline 8012.
In heart valve prosthesis 800 provided in this embodiment, when proximal end ring cavity 807a, which is in, to be taken out under flat state, proximal loop
Chamber 807a is shunk under natural resiliency effect, so that the outer profile of the proximal end 803 of the heart valve prosthesis generates by a relatively large margin
It reduces, as illustrated in figs. 12 a and 12b, the proximal end 803 of the heart valve prosthesis is allowed to be easier to pass through master in traction action
Artery annulus.
In some embodiments, the elasticity modulus of the material of proximal end ring cavity 807a, less than the material of distal end ring cavity 807b
Elasticity modulus.The fill-media-free in the ring cavity 807a of proximal end, when to take out under flat state, the week of the outer profile of proximal end ring cavity 807a
The perimeter of the long outer profile less than distal end ring cavity 807b, so that the shape of the heart valve prosthesis 800 is substantially tapered, it is convenient to be somebody's turn to do
Aortic valvular ring is passed through in the proximal end 803 of heart valve prosthesis.
Ring cavity 807b flexible amplitude under the action of filled media in distal end is smaller or non-telescope.Proximal end ring cavity 807a is from filling
To flat state is taken out contraction by a relatively large margin can occur for the state that is full of.Proximal end ring cavity 807a uses elastic material, since elastic material is logical
Often with the trend that the shape and size of oriented determination are shunk, thus proximal end ring cavity 807a is can be shrunk to smaller in the case where taking out flat state
The circular ring shape of size, so that the outer profile of the proximal end 803 of the heart valve prosthesis is smaller, it is easier to pass through aortic valvular ring.
Further, by proximal loop chamber 807a to be unfolded shown in Figure 11, proximal end ring cavity 807a is made to keep straight.In proximal loop
In the case that chamber 807a is unfolded in this way, as shown in fig. 15, under expanded state, the Zhou Changwei L of proximal end ring cavity 807a, directly
Diameter is D;As shown in fig. 15b, in the case where taking out flat state, the Zhou Changwei L of proximal end ring cavity 807a, diameter D.Meet following relationship:
As shown in fig. 15 a and fig. 15b, in one embodiment of the present invention, the proximal end ring cavity 807a under expanded state
The perimeter of outer profile is denoted as L, and in the case where taking out flat state, the perimeter of the outer profile of proximal end ring cavity 807a is denoted as L, meets following relationship:
150%≤(L/L ')≤500%.
Further, meet following relationship:
200%≤(L/L ')≤450%.
Further, meet following relationship:
250%≤(L/L ')≤400%.
In one embodiment of the present invention, the tolerable burst pressure of proximal end ring cavity 807a is greater than or equal to 5atm.
Further, the tolerable burst pressure of proximal end ring cavity 807a is greater than or equal to 16atm.
In one embodiment of the present invention, the material of proximal end ring cavity 807a includes PVC, thermoplastic elastomer (TPE), latex, silicon
Wantonly a kind of monomer or a variety of mixed complexs of more than two kinds in rubber.Preferably, in some cases, proximal end ring cavity
The material of 807a includes thermoplasticity body, such as Chronoprene;In other cases, the material packet of proximal end ring cavity 807a
Include polyether-block-polyamide, such as Pebax.
Nylon, polyethylene fibre or polyethers acyl etc. can be used in distal end ring cavity 807b and the material of column sections 806 can
Maintain the material of pressure.In production, proximal end ring cavity 807a, column sections 806 and distal end ring cavity 807b can be separated and be formed, molding
After be secured to together.
In one embodiment of the present invention, circlecuf 802 uses flexible material, and has preferable plastic property,
The stroke of circlecuf 802 under external force is smaller or does not stretch, under expanded state, 8011 energy of proximal annular rim pipeline
Enough ring cavity 807a chamber in proximal end is prevented to expand outwardly, the shape and size of the proximal end 803 of the heart valve prosthesis are by proximal annular rim pipe
Road 8011 limits, and leads to fillable structure breaking to avoid the unordered expansion of fillable structure 813 or part expansion are excessive.Example
Such as, the warp 8022 and weft 8021 made in the fabric of circlecuf 802 is all made of and non-resilient knits line.
The foregoing is merely several embodiments of the present invention, and those skilled in the art is according to application documents disclosure
Various changes or modifications can be carried out without departing from the spirit and scope of the present invention to the embodiment of the present invention.
Claims (15)
1. a kind of heart valve prosthesis characterized by comprising
Circlecuf, has the inner surface for limiting blood flow path, and one end of the circlecuf is equipped with proximal annular rim pipeline, institute
The other end for stating circlecuf is equipped with distal annular rim pipeline;
Valve is positioned in the blood flow path and is connected to the circlecuf, and the valve can allow for the blood flow
The flowing in the direction of the proximal annular rim pipeline is directed toward in path along the distal annular rim pipeline, and is prevented in the blood flow path
The flowing in the direction of the distal annular rim pipeline is directed toward along the proximal annular rim pipeline;
It is connected to the fillable structure of the circlecuf, with proximal end ring cavity and distal end ring cavity, the proximal annular rim pipeline
Wrap up the proximal end ring cavity, distal end ring cavity described in the distal annular rim duct wraps;The proximal end ring cavity has to contract
Trend, to reduce the perimeter of the outer profile of the proximal end ring cavity.
2. heart valve prosthesis according to claim 1, which is characterized in that the material of the proximal end ring cavity is using elastic material
Material;In the case where the proximal end ring cavity is to take out flat state, the perimeter of the outer profile of the proximal annular rim pipeline is less than described remote
Hold the perimeter of the outer profile of circulating line.
3. heart valve prosthesis according to claim 2, which is characterized in that the springform of the material of the proximal end ring cavity
Amount, less than the elasticity modulus of the material of the distal end ring cavity.
4. heart valve prosthesis according to claim 3, which is characterized in that under expanded state, the foreign steamer of proximal end ring cavity
Wide Zhou Changwei L, diameter D;
In the case where taking out flat state, the Zhou Changwei L ' of the outer profile of proximal end ring cavity, diameter is D ';
Meet following relationship:
(D/D ') < (L/L ').
5. heart valve prosthesis according to claim 2, which is characterized in that the outer profile of proximal end ring cavity under expanded state
Perimeter L, in the case where taking out flat state the perimeter L of the outer profile of proximal end ring cavity ';
Meet following relationship:
150%≤(L/L ')≤500%.
6. heart valve prosthesis according to claim 5, which is characterized in that meet following relationship:
200%≤(L/L ')≤450%.
7. heart valve prosthesis according to claim 6, which is characterized in that meet following relationship:
250%≤(L/L ')≤400%.
8. heart valve prosthesis according to claim 2, which is characterized in that the tolerable burst pressure of the proximal end ring cavity is big
In or equal to 5atm.
9. heart valve prosthesis according to claim 8, which is characterized in that the tolerable burst pressure of the proximal end ring cavity is big
In or equal to 16atm.
10. heart valve prosthesis according to claim 2, which is characterized in that the material of the proximal end ring cavity include PVC,
Thermoplastic elastomer (TPE), latex, wantonly a kind of the monomer in silicon rubber appoint a variety of mixed complexs of more than two kinds.
11. heart valve prosthesis according to claim 10, which is characterized in that the material of the proximal end ring cavity includes
Chronoprene or Pebax.
12. heart valve prosthesis according to claim 1, which is characterized in that the proximal annular rim pipeline can prevent institute
The outer profile for stating proximal end ring cavity expands outwardly.
13. heart valve prosthesis according to claim 1, which is characterized in that the fillable structure includes set on described
Column sections between proximal end ring cavity and the distal end ring cavity;The proximal end ring cavity and the leg portion are split into type, and are fixed in
Together.
14. heart valve prosthesis according to claim 1, which is characterized in that the heart valve prosthesis and aorta petal
Ring is adapted.
15. it is false to be applied to the described in any item heart valves of claim 1-14 for a kind of fillable structure of heart valve prosthesis
Body characterized by comprising proximal end ring cavity, distal end ring cavity and the branch between the proximal end ring cavity and the distal end ring cavity
Column portion;
The material of the proximal end ring cavity uses elastic material, so that the proximal end ring cavity is had the trend to contract, to reduce
State the perimeter of the outer profile of proximal end ring cavity.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910864378.9A CN110478085B (en) | 2019-09-12 | 2019-09-12 | Heart valve prosthesis and fillable structure thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910864378.9A CN110478085B (en) | 2019-09-12 | 2019-09-12 | Heart valve prosthesis and fillable structure thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110478085A true CN110478085A (en) | 2019-11-22 |
CN110478085B CN110478085B (en) | 2022-05-17 |
Family
ID=68557920
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910864378.9A Active CN110478085B (en) | 2019-09-12 | 2019-09-12 | Heart valve prosthesis and fillable structure thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110478085B (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114495669A (en) * | 2022-02-17 | 2022-05-13 | 北京理工大学 | A composite material for bionic organs |
CN117771024A (en) * | 2024-02-22 | 2024-03-29 | 上海市医疗器械检验研究院 | Prosthetic heart valve endurance test device and method thereof |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110160846A1 (en) * | 2007-08-23 | 2011-06-30 | Direct Flow Medical, Inc. | Translumenally implantable heart valve with formed in place support |
US20120016468A1 (en) * | 2010-05-19 | 2012-01-19 | Direct Flow Medical, Inc. | Low crossing profile delivery catheter for cardiovascular prosthetic implant |
US20120022629A1 (en) * | 2010-05-19 | 2012-01-26 | Direct Flow Medical, Inc. | Inflation media for implants |
CN104602646A (en) * | 2012-05-01 | 2015-05-06 | 直接流医疗有限公司 | Prosthetic implant delivery device with introducer catheter |
US20150327995A1 (en) * | 2014-05-16 | 2015-11-19 | St. Jude Medical, Cardiology Division, Inc. | Transcatheter valve with paravalvular leak sealing ring |
CN105232187A (en) * | 2011-09-09 | 2016-01-13 | 安多拉米诺科学公司 | Means for controlled sealing of endovascular devices |
CN106794064A (en) * | 2014-08-15 | 2017-05-31 | 直流医疗有限责任公司 | Prothesis implant body conveying device |
US20170157376A1 (en) * | 2006-10-19 | 2017-06-08 | Direct Flow Medical, Inc. | Catheter guidance through a calcified aortic valve |
-
2019
- 2019-09-12 CN CN201910864378.9A patent/CN110478085B/en active Active
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20170157376A1 (en) * | 2006-10-19 | 2017-06-08 | Direct Flow Medical, Inc. | Catheter guidance through a calcified aortic valve |
US20110160846A1 (en) * | 2007-08-23 | 2011-06-30 | Direct Flow Medical, Inc. | Translumenally implantable heart valve with formed in place support |
US20120016468A1 (en) * | 2010-05-19 | 2012-01-19 | Direct Flow Medical, Inc. | Low crossing profile delivery catheter for cardiovascular prosthetic implant |
US20120022629A1 (en) * | 2010-05-19 | 2012-01-26 | Direct Flow Medical, Inc. | Inflation media for implants |
CN105232187A (en) * | 2011-09-09 | 2016-01-13 | 安多拉米诺科学公司 | Means for controlled sealing of endovascular devices |
CN104602646A (en) * | 2012-05-01 | 2015-05-06 | 直接流医疗有限公司 | Prosthetic implant delivery device with introducer catheter |
US20150327995A1 (en) * | 2014-05-16 | 2015-11-19 | St. Jude Medical, Cardiology Division, Inc. | Transcatheter valve with paravalvular leak sealing ring |
CN106794064A (en) * | 2014-08-15 | 2017-05-31 | 直流医疗有限责任公司 | Prothesis implant body conveying device |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114495669A (en) * | 2022-02-17 | 2022-05-13 | 北京理工大学 | A composite material for bionic organs |
CN114495669B (en) * | 2022-02-17 | 2022-10-28 | 北京理工大学 | Composite material for bionic visceral organ |
CN117771024A (en) * | 2024-02-22 | 2024-03-29 | 上海市医疗器械检验研究院 | Prosthetic heart valve endurance test device and method thereof |
Also Published As
Publication number | Publication date |
---|---|
CN110478085B (en) | 2022-05-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220265424A1 (en) | Prosthetic implant delivery device with introducer catheter | |
US10478299B2 (en) | Low crossing profile delivery catheter for cardiovascular prosthetic implant | |
CN106794064B (en) | Prothesis implant body conveying device | |
CN105246431B (en) | Implantable cardiac valve device, mitral valve repair device and related system and method | |
CN105455924B (en) | For treating the implantable device of heart valve regurgitation | |
ES2407684T3 (en) | Heart valve without stent with support structure formed on site | |
CA2571047C (en) | Paravalvular leak detection, sealing and prevention | |
KR20190020038A (en) | Heart valve recovery device and method of implanting the same | |
CN109475411A (en) | two-part mitral valve | |
CN110478086A (en) | Heart valve prosthesis | |
CN109414322A (en) | A kind of artificial valve | |
CN109561961A (en) | A kind of artificial valve and artificial valve method for implantation | |
CN107920895A (en) | Implantable cardiac valve device, mitral valve repair device and related system and method | |
CN105263443A (en) | Sutureless valve prosthesis delivery device and methods of use thereof | |
CN102458309A (en) | Unitary quick-connect prosthetic heart valve and deployment system and methods | |
CN108348321A (en) | Heart valve | |
CN111214311B (en) | Heart valve prosthesis and fillable tube | |
CN110478085A (en) | Heart valve prosthesis and its fillable structure | |
CN110478087A (en) | Heart valve prosthesis | |
CN208974213U (en) | A kind of unobstructed heart valve implanted medical balloon | |
CN117320670A (en) | Sealing and anchoring mechanism for internal irregular tissue and sealing and anchoring method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |